Management of inflammation by natural polyphenols: A comprehensive mechanistic update

Current Medicinal Chemistry

Volumn 23, Issue 16, 2016, Pages 1657-1695

  Sarkar, Souvik ^a   Mazumder, Somnath ^a   Saha, Shubhra J ^a   Bandyopadhyay, Uday ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Bioavailability; Curcumin; Formulations; Liposomes; Micelles; Nanoparticles; Prodrug; Quercetin; Resveratrol

Indexed keywords

COUMARIN DERIVATIVE; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; FLAVONOID; NONSTEROID ANTIINFLAMMATORY AGENT; POLYPHENOL; QUERCETIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; STILBENE DERIVATIVE; BIOLOGICAL PRODUCT;

ANTIINFLAMMATORY ACTIVITY; CHEMICAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; HUMAN; INFLAMMATION; MEDICINAL CHEMISTRY; OXIDATIVE STRESS; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; BIOAVAILABILITY; METABOLISM; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; BIOLOGICAL PRODUCTS; HUMANS; INFLAMMATION; POLYPHENOLS; REACTIVE OXYGEN SPECIES;

EID: 84973649713     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666160418115540     Document Type: Review

References (370)

1. Flower, R. J.; Vane, J. R. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature, 1972, 240(5381), 410-411.
2. Bjarnason, I.; Hayllar, J.; MacPherson, A. J.; Russell, A. S. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology, 1993, 104(6), 1832-1847.
3. Harirforoosh, S.; Jamali, F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin. Drug Saf., 2009, 8(6), 669-681.
4. Trelle, S.; Reichenbach, S.; Wandel, S.; Hildebrand, P.; Tschannen, B.; Villiger, P. M.; Egger, M.; Jüni, P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ, 2011, 342, c7086.
5. McGettigan, P.; Henry, D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA, 2006, 296(13), 1633-1644.
6. Williams, R. J.; Spencer, J. P.; Rice-Evans, C. Flavonoids: antioxidants or signalling molecules? Free Radic. Biol. Med., 2004, 36(7), 838-849.
7. Mattia, C.; Coluzzi, F. COX-2 inhibitors: pharmacological data and adverse effects. Minerva Anestesiol., 2005, 71(7-8), 461-470.
8. Medzhitov, R. Origin and physiological roles of inflammation. Nature, 2008, 454(7203), 428-435.
9. Soehnlein, O.; Lindbom, L. Phagocyte partnership during the onset and resolution of inflammation. Nat. Rev. Immunol., 2010, 10(6), 427-439.
10. Blasko, I.; Stampfer-Kountchev, M.; Robatscher, P.; Veerhuis, R.; Eikelenboom, P.; Grubeck-Loebenstein, B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell, 2004, 3(4), 169-176.
11. Eikelenboom, P.; Rozemuller, J. M.; Van Muiswinkel, F. L. Inflammation and Alzheimer's disease: relationships between pathogenic mechanisms and clinical expression. Exp. Neurol., 1998, 154(1), 89-98.
12. Whitton, P. S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol., 2007, 150(8), 963-976.
13. Hall, J. C.; Crawford, H. C. The conspiracy of autophagy, stress and inflammation in acute pancreatitis. Curr. Opin. Gastroenterol., 2014, 30(5), 495-499.
14. Kumar, H.; Kawai, T.; Akira, S. Pathogen recognition by the innate immune system. Int. Rev. Immunol., 2011, 30(1), 16-34.
15. Tabas, I.; Glass, C. K. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science, 2013, 339(6116), 166-172.
16. Ferrero-Miliani, L.; Nielsen, O. H.; Andersen, P. S.; Girardin, S. E. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. Clin. Exp. Immunol,. 2007, 147(2), 227-235.
17. Duffield, J. S. The inflammatory macrophage: a story of Jekyll and Hyde. Clin. Sci., 2003, 104(1), 27-38.
18. Nathan, C. Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol., 2006, 6(3), 173-182.
19. Serhan, C. N.; Brain, S. D.; Buckley, C. D.; Gilroy, D. W.; Haslett, C.; O'Neill, L. A.; Perretti, M.; Rossi, A. G.; Wallace, J. L. Resolution of inflammation: state of the art, definitions and terms. FASEB J., 2007, 21(2), 325-332.
20. Lawrence, T.; Gilroy, D. W. Chronic inflammation: a failure of resolution? Int. J. Exp. Pathol., 2007, 88(2), 85-94.
21. Serhan, C. N.; Savill, J. Resolution of inflammation: the beginning programs the end. Nat. Immunol., 2005, 6(12), 1191-1197.
22. Serhan, C. N. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol., 2007, 25, 101-137.
23. Martinez, F. O.; Helming, L.; Gordon, S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol., 2009, 27, 451-483.
24. Roman-Blas, J. A.; Jimenez, S. A. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis Osteoarthritis and cartilage/OARS. Osteoarthr. Res. Soc., 2006, 14(9), 839-848.
25. Packer, L.; Suzuki, Y. J. Oxidative Stress, Cell Activation and Viral Infection; Pasquier, C.; Olivier, R. Y.; Auclair, C.; Packer, L., Eds.; Birkhäuser Basel: Basel, 1994, pp. 113-130.
26. Jobin, C.; Bradham, C. A.; Russo, M. P.; Juma, B.; Narula, A. S.; Brenner, D. A.; Sartor, R. B. Curcumin blocks cytokinemediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J. Immunol., 1999, 163(6), 3474-3483.
27. Ruiz, P. A.; Braune, A.; Holzlwimmer, G.; Quintanilla-Fend, L.; Haller, D. Quercetin inhibits TNF-induced NFkappaB transcription factor recruitment to proinflammatory gene promoters in murine intestinal epithelial cells. J. Nutr., 2007, 137(5), 1208-1215.
28. Ren, Z.; Wang, L.; Cui, J.; Huoc, Z.; Xue, J.; Cui, H.; Mao, Q.; Yang, R. Resveratrol inhibits NF-kB signaling through suppression of p65 and IkappaB kinase activities. Pharmazie, 2013, 68(8), 689-694.
29. Miller, S. C.; Huang, R.; Sakamuru, S.; Shukla, S. J.; Attene-Ramos, M. S.; Shinn, P.; Van Leer, D.; Leister, W.; Austin, C. P.; Xia, M. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem. Pharmacol., 2010, 79(9), 1272-1280.
30. Li, Z.; Geng, Y. N.; Jiang, J. D.; Kong, W. J. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid.-based Complement. Alternat. Med., 2014, 2014, 289264.
31. Manna, S. K.; Mukhopadhyay, A.; Aggarwal, B. B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol., 2000, 164(12), 6509-6519.
32. Ding, M.; Zhao, J.; Bowman, L.; Lu, Y.; Shi, X. Inhibition of AP-1 and MAPK signaling and activation of Nrf2/ARE pathway by quercitrin. Int. J. Oncol., 2010, 36(1), 59-67.
33. Xu, Y. X.; Pindolia, K. R.; Janakiraman, N.; Chapman, R. A.; Gautam, S. C. Curcumin inhibits IL1 alpha and TNF-alpha induction of AP-1 and NF-kB DNA-binding activity in bone marrow stromal cells. Hematopathol. Mol. Hematol., 1997-1998, 11(1), 49-62.
34. Oh, J.; Kim, J. H.; Park, J. G.; Yi, Y. S.; Park, K. W.; Rho, H. S.; Lee, M. S.; Yoo, J. W.; Kang, S. H.; Hong, Y. D.; Shin, S. S.; Cho, J. Y. Radical scavenging activity-based and AP-1-targeted anti-inflammatory effects of lutein in macrophagelike and skin keratinocytic cells. Mediat. Inflamm., 2013, 2013, 787042.
35. Schafer, M.; Werner, S. Oxidative stress in normal and impaired wound repair. Pharmacol. Res., 2008, 58(2), 165-171.
36. Mittal, M.; Siddiqui, M. R.; Tran, K.; Reddy, S. P.; Malik, A. B. Reactive oxygen species in inflammation and tissue injury. Antioxid. Redox Signal., 2014, 20(7), 1126-1167.
37. Chan, W. H.; Wu, H. J. Protective effects of curcumin on methylglyoxal-induced oxidative DNA damage and cell injury in human mononuclear cells. Acta Pharmacol. Sin., 2006, 27(9), 1192-1198.
38. Park, D. W.; Baek, K.; Kim, J. R.; Lee, J. J.; Ryu, S. H.; Chin, B. R.; Baek, S. H. Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species and monocyte chemotactic protein-1. Exp. Mol. Med., 2009, 41(3), 171-179.
39. Chen, Y. W.; Chou, H. C.; Lin, S. T.; Chen, Y. H.; Chang, Y. J.; Chen, L.; Chan, H. L. Cardioprotective effects of quercetin in cardiomyocyte under ischemia/reperfusion injury. Evid-Based Compliment. Alternat. Med., 2013, 2013, 364-519.
40. Gorlach, A.; Dimova, E. Y.; Petry, A.; Martinez-Ruiz, A.; Hernansanz-Agustin, P.; Rolo, A. P.; Palmeira, C. M.; Kietzmann, T. Reactive oxygen species, nutrition, hypoxia and diseases: Problems solved? Redox Biol., 2015, 6, 372-385.
41. Gloire, G.; Legrand-Poels, S.; Piette, J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol., 2006, 72(11), 1493-1505.
42. Engelhardt, J. F. Redox-mediated gene therapies for environmental injury: approaches and concepts. Antioxid. Redox Signal., 1999, 1(1), 5-27.
43. Rhee, S. G.; Chang, T. S.; Bae, Y. S.; Lee, S. R.; Kang, S. W. Cellular regulation by hydrogen peroxide. J. Am. Soc. Nephrol., 2003, 14(8) (Suppl. 3), S211-S215.
44. Mieczyslaw, P. Mangiferin-A nutraceutical with clinical implications. Vitam. Miner., 2014, 3, 1-3.
45. Leopoldini, M.; Russo, N.; Chiodo, S.; Toscano, M. Iron chelation by the powerful antioxidant flavonoid quercetin. J. Agric. Food Chem., 2006, 54(17), 6343-6351.
46. Jiao, Y.; Wilkinson, J., IV; Christine Pietsch, E.; Buss, J. L.; Wang, W.; Planalp, R.; Torti, F. M.; Torti, S. V. Iron chelation in the biological activity of curcumin. Free Radic. Biol. Med., 2006, 40(7), 1152-1160.
47. Bindu, S.; Mazumder, S.; Dey, S.; Pal, C.; Goyal, M.; Alam, A.; Iqbal, M. S.; Sarkar, S.; Azhar Siddiqui, A.; Banerjee, C.; Bandyopadhyay, U. Nonsteroidal antiinflammatory drug induces proinflammatory damage in gastric mucosa through NF-κB activation and neutrophil infiltration: anti-inflammatory role of heme oxygenase-1 against nonsteroidal anti-inflammatory drug. Free Radic. Biol. Med., 2013, 65, 456-467.
48. Ferreira, S. H. Peripheral analgesic sites of action of antiinflammatory drugs. Int. J. Clin. Pract. Suppl., 2002, (128), 2-10.
49. Conaghan, P. G. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol. Int., 2012, 32(6), 1491-1502.
50. Bleumink, G. S.; Feenstra, J.; Sturkenboom, M. C.; Stricker, B. H. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs, 2003, 63(6), 525-534.
51. Patrignani, P. Nonsteroidal anti-inflammatory drugs, COX-2 and colorectal cancer. Toxicol. Lett., 2000, 112-113, 493-498.
52. Zhao, S. Z.; Reynolds, M. W.; Lejkowith, J.; Whelton, A.; Arellano, F. M. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin. Ther., 2001, 23(9), 1478-1491.
53. Suleyman, H.; Demircan, B.; Karagoz, Y. Antiinflammatory and side effects of cyclooxygenase inhibitors. Pharmacol. Rep., 2007, 59(3), 247-258.
54. Essex, M. N.; Zhang, R. Y.; Berger, M. F.; Upadhyay, S.; Park, P. W. Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials. Expert Opin. Drug Saf., 2013, 12(4), 465-477.
55. Meagher, E. A. Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: clinical implications. Drug Saf., 2003, 26(13), 913-924.
56. Van Staa, T. P.; Leufkens, H. G.; Abenhaim, L.; Begaud, B.; Zhang, B.; Cooper, C. Use of oral corticosteroids in the United Kingdom. QJM, 2000, 93(2), 105-111.
57. Wei, L.; MacDonald, T. M.; Walker, B. R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann. Intern. Med., 2004, 141(10), 764-770.
58. Souverein, P. C.; Berard, A.; Van Staa, T. P.; Cooper, C.; Egberts, A. C.; Leufkens, H. G.; Walker, B. R. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart, 2004, 90(8), 859-865.
59. De Vries, F.; Pouwels, S.; Lammers, J. W.; Leufkens, H. G.; Bracke, M.; Cooper, C.; Van Staa, T. P. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J. Intern. Med., 2007, 261(2), 170-177.
60. Vegiopoulos, A.; Herzig, S. Glucocorticoids, metabolism and metabolic diseases. Mol. Cell. Endocrinol., 2007, 275(1-2), 43-61.
61. Stahn, C.; Löwenberg, M.; Hommes, D. W.; Buttgereit, F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol. Cell. Endocrinol., 2007, 275(1-2), 71-78.
62. Buttgereit, F.; Saag, K. G.; Cutolo, M.; Da Silva, J. A.; Bijlsma, J. W. The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand. J. Rheumatol., 2005, 34(1), 14-21.
63. Perretti, M.; Ahluwalia, A. The microcirculation and inflammation: site of action for glucocorticoids. Microcirculation, 2000, 7(3), 147-161.
64. Ashwell, J. D.; Lu, F. W.; Vacchio, M. S. Glucocorticoids in T cell development and function. Annu. Rev. Immunol., 2000, 18, 309-345.
65. McEwen, B. S.; Biron, C. A.; Brunson, K. W.; Bulloch, K.; Chambers, W. H.; Dhabhar, F. S.; Goldfarb, R. H.; Kitson, R. P.; Miller, A. H.; Spencer, R. L.; Weiss, J. M. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res. Brain Res. Rev., 1997, 23(1-2), 79-133.
66. Barnes, P. J. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci., 1998, 94(6), 557-572.
67. Smoak, K. A.; Cidlowski, J. A. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech. Ageing Dev., 2004, 125(10-11), 697-706.
68. Schäcke, H.; Schottelius, A.; Döcke, W. D.; Strehlke, P.; Jaroch, S.; Schmees, N.; Rehwinkel, H.; Hennekes, H.; Asadullah, K. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl. Acad. Sci. USA, 2004, 101(1), 227-232.
69. Schäcke, H.; Döcke, W. D.; Asadullah, K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther., 2002, 96(1), 23-43.
70. Bravo, L. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr. Rev., 1998, 56(11), 317-333.
71. Leiro, J.; Alvarez, E.; Arranz, J. A.; Laguna, R.; Uriarte, E.; Orallo, F. Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes. J. Leukoc. Biol., 2004, 75(6), 1156-1165.
72. Harborne, J. B.; Williams, C. A. Advances in flavonoid research since 1992. Phytochemistry, 2000, 55(6), 481-504.
73. Cheynier, V. Polyphenols in foods are more complex than often thought. Am. J. Clin. Nutr., 2005, 81(Suppl. 1), 223S-229S.
74. Liu, R. H. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J. Nutr., 2004, 134(Suppl. 12), 3479S-3485S.
75. De Lange, D. W. From red wine to polyphenols and back: a journey through the history of the French Paradox. Thromb. Res., 2007, 119(4), 403-406.
76. De Lorgeril, M.; Salen, P.; Martin, J. L.; Monjaud, I.; Delaye, J.; Mamelle, N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation, 1999, 99(6), 779-785.
77. Zern, T. L.; Fernandez, M. L. Cardioprotective effects of dietary polyphenols. J. Nutr., 2005, 135(10), 2291-2294.
78. Goswami, S. K.; Das, D. K. Resveratrol and chemoprevention. Cancer Lett., 2009, 284(1), 1-6.
79. Campagna, M.; Rivas, C. Antiviral activity of resveratrol. Biochem. Soc. Trans., 2010, 38(Pt 1), 50-53.
80. De La Lastra, C. A.; Villegas, I. Resveratrol as an antiinflammatory and anti-aging agent: mechanisms and clinical implications. Mol. Nutr. Food Res., 2005, 49(5), 405-430.
81. ∗NO bioavailability: Potential benefits to cardiovascular diseases. Biochimie, 2012, 94(2), 269-276.
82. Fulda, S. Regulation of cell death and survival by resveratrol: implications for cancer therapy. Anticancer. Agents Med. Chem., 2012, 12(8), 874-879.
83. Szekeres, T.; Fritzer-Szekeres, M.; Saiko, P.; Jäger, W. Resveratrol and resveratrol analogues-structure-activity relationship. Pharm. Res., 2010, 27(6), 1042-1048.
84. Antus, C.; Radnai, B.; Dombovari, P.; Fonai, F.; Avar, P.; Matyus, P.; Racz, B.; Sumegi, B.; Veres, B. Antiinflammatory effects of a triple-bond resveratrol analog: structure and function relationship. Eur. J. Pharmacol., 2015, 748, 61-67.
85. Chen, W.; Ge, X.; Xu, F.; Zhang, Y.; Liu, Z.; Pan, J.; Song, J.; Dai, Y.; Zhou, J.; Feng, J.; Liang, G. Design, synthesis and biological evaluation of paralleled Aza resveratrolchalcone compounds as potential anti-inflammatory agents for the treatment of acute lung injury. Bioorg. Med. Chem. Lett., 2015, 25(15), 2998-3004.
86. Kim, M. H.; Son, Y. J.; Lee, S. Y.; Yang, W. S.; Yi, Y. S.; Yoon, D. H.; Yang, Y.; Kim, S. H.; Lee, D.; Rhee, M. H.; Kang, H.; Kim, T. W.; Sung, G. H.; Cho, J. Y. JAK2-targeted anti-inflammatory effect of a resveratrol derivative 2, 4-dihydroxy-N-(4-hydroxyphenyl) benzamide. Biochem. Pharmacol., 2013, 86(12), 1747-1761.
87. Bae, S. J.; Ha, Y. M.; Kim, J. A.; Park, J. Y.; Ha, T. K.; Park, D.; Chun, P.; Park, N. H.; Moon, H. R.; Chung, H. Y. A novel synthesized tyrosinase inhibitor: (E)-2-((2, 4-dihydroxy-phenyl) diazenyl) phenyl 4-methylbenzenesulfonate as an azo-resveratrol analog. Biosci. Biotechnol. Biochem., 2013, 77(1), 65-72.
88. Song, Y. M.; Ha, Y. M.; Kim, J. A.; Chung, K. W.; Uehara, Y.; Lee, K. J.; Chun, P.; Byun, Y.; Chung, H. Y.; Moon, H. R. Synthesis of novel azo-resveratrol, azo-oxyresveratrol and their derivatives as potent tyrosinase inhibitors. Bioorg. Med. Chem. Lett., 2012, 22(24), 7451-7455.
89. Son, Y.; Lee, J. H.; Chung, H. T.; Pae, H. O. Therapeutic roles of heme oxygenase-1 in metabolic diseases: curcumin and resveratrol analogues as possible inducers of heme oxygenase-1. Oxid. Med. Cell. Longer., 2013, 2013, 639541.
90. Li, C.; Xu, X.; Wang, X. J.; Pan, Y. Imine resveratrol analogues: molecular design, Nrf2 activation and SAR analysis. PLoS One, 2014, 9(7), e101455.
91. Mattarei, A.; Azzolini, M.; La Spina, M.; Zoratti, M.; Paradisi, C.; Biasutto, L. Amino acid carbamates as prodrugs of resveratrol. Sci. Rep., 2015, 5, 15216.
92. Mattarei, A.; Azzolini, M.; Zoratti, M.; Biasutto, L.; Paradisi, C. N-monosubstituted methoxy-oligo (ethylene glycol) carbamate ester prodrugs of resveratrol. Molecules, 2015, 20(9), 16085-16102.
93. Azzolini, M.; Mattarei, A.; La Spina, M.; Marotta, E.; Zoratti, M.; Paradisi, C.; Biasutto, L. Synthesis and evaluation as prodrugs of hydrophilic carbamate ester analogues of resveratrol. Mol. Pharm., 2015, 12(9), 3441-3454.
94. Wang, B.; Sun, J.; Li, X.; Zhou, Q.; Bai, J.; Shi, Y.; Le, G. Resveratrol prevents suppression of regulatory T-cell production, oxidative stress, and inflammation of mice prone or resistant to high-fat diet-induced obesity. Nutr. Res., 2013, 33(11), 971-981.
95. Price, N. L.; Gomes, A. P.; Ling, A. J.; Duarte, F. V.; Martin-Montalvo, A.; North, B. J.; Agarwal, B.; Ye, L.; Ramadori, G.; Teodoro, J. S.; Hubbard, B. P.; Varela, A. T.; Davis, J. G.; Varamini, B.; Hafner, A.; Moaddel, R.; Rolo, A. P.; Coppari, R.; Palmeira, C. M.; De Cabo, R.; Baur, J. A.; Sinclair, D. A. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab., 2012, 15(5), 675-690.
96. Rivera, L.; Morón, R.; Zarzuelo, A.; Galisteo, M. Longterm resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem. Pharmacol., 2009, 77(6), 1053-1063.
97. Gómez-Zorita, S.; Fernández-Quintela, A.; Lasa, A.; Hijona, E.; Bujanda, L.; Portillo, M. P. Effects of resveratrol on obesity-related inflammation markers in adipose tissue of genetically obese rats. Nutrition, 2013, 29(11-12), 1374-1380.
98. Jeon, B. T.; Jeong, E. A.; Shin, H. J.; Lee, Y.; Lee, D. H.; Kim, H. J.; Kang, S. S.; Cho, G. J.; Choi, W. S.; Roh, G. S. Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. Diabetes, 2012, 61(6), 1444-1454.
99. Martín, A. R.; Villegas, I.; Sánchez-Hidalgo, M.; De La Lastra, C. A. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br. J. Pharmacol., 2006, 147(8), 873-885.
100. Jimenez-Gomez, Y.; Mattison, J. A.; Pearson, K. J.; Martin-Montalvo, A.; Palacios, H. H.; Sossong, A. M.; Ward, T. M.; Younts, C. M.; Lewis, K.; Allard, J. S.; Longo, D. L.; Belman, J. P.; Malagon, M. M.; Navas, P.; Sanghvi, M.; Moaddel, R.; Tilmont, E. M.; Herbert, R. L.; Morrell, C. H.; Egan, J. M.; Baur, J. A.; Ferrucci, L.; Bogan, J. S.; Bernier, M.; De Cabo, R. Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet. Cell Metab., 2013, 18(4), 533-545.
101. Elmali, N.; Baysal, O.; Harma, A.; Esenkaya, I.; Mizrak, B. Effects of resveratrol in inflammatory arthritis. Inflammation, 2007, 30(1-2), 1-6.
102. Elmali, N.; Esenkaya, I.; Harma, A.; Ertem, K.; Turkoz, Y.; Mizrak, B. Effect of resveratrol in experimental osteoarthritis in rabbits. Inflamm. Res., 2005, 54(4), 158-162.
103. Kim, H. J.; Braun, H. J.; Dragoo, J. L. The effect of resveratrol on normal and osteoarthritic chondrocyte metabolism. Bone Joint Res., 2014, 3(3), 51-59.
104. Liu, F. C.; Hung, L. F.; Wu, W. L.; Chang, D. M.; Huang, C. Y.; Lai, J. H.; Ho, L. J. Chondroprotective effects and mechanisms of resveratrol in advanced glycation end productsstimulated chondrocytes. Arthritis Res. Ther., 2010, 12(5), R167.
105. Bereswill, S.; Muñoz, M.; Fischer, A.; Plickert, R.; Haag, L. M.; Otto, B.; Kühl, A. A.; Loddenkemper, C.; Göbel, U. B.; Heimesaat, M. M. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS One, 2010, 5(12), e15099.
106. Larrosa, M.; Yañéz-Gascón, M. J.; Selma, M. V.; González-Sarrías, A.; Toti, S.; Cerón, J. J.; Tomás-Barberán, F.; Dolara, P.; Espín, J. C. Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J. Agric. Food Chem., 2009, 57(6), 2211-2220.
107. Lee, M.; Kim, S.; Kwon, O. K.; Oh, S. R.; Lee, H. K.; Ahn, K. Anti-inflammatory and anti-asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of allergic asthma. Int. Immunopharmacol., 2009, 9(4), 418-424.
108. Royce, S. G.; Dang, W.; Yuan, G.; Tran, J.; El Osta, A.; Karagiannis, T. C.; Tang, M. L. Resveratrol has protective effects against airway remodeling and airway hyperreactivity in a murine model of allergic airways disease. Pathobiol. Aging Age Relat. Dis., 2011, 1, 1.
109. Poulsen, M. M.; Larsen, J. O.; Hamilton-Dutoit, S.; Clasen, B. F.; Jessen, N.; Paulsen, S. K.; Kjær, T. N.; Richelsen, B.; Pedersen, S. B. Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. Nutr. Res., 2012, 32(9), 701-708.
110. Coradini, K.; Friedrich, R. B.; Fonseca, F. N.; Vencato, M. S.; Andrade, D. F.; Oliveira, C. M.; Battistel, A. P.; Guterres, S. S.; Da Rocha, M. I.; Pohlmann, A. R.; Beck, R. C. A novel approach to arthritis treatment based on resveratrol and curcumin co-encapsulated in lipid-core nanocapsules: In vivo studies Eur. J. Pharmaceut. Sci., 2015, 78, 163-170.
111. Wang, H. L.; Gao, J. P.; Han, Y. L.; Xu, X.; Wu, R.; Gao, Y.; Cui, X. H. Comparative studies of polydatin and resveratrol on mutual transformation and antioxidative effect in vivo. Phytomedicine, 2015, 22(5), 553-559.
112. Little, J. P.; Safdar, A.; Wilkin, G. P.; Tarnopolsky, M. A.; Gibala, M. J. A practical model of low-volume highintensity interval training induces mitochondrial biogenesis in human skeletal muscle: potential mechanisms. J. Physiol., 2010, 588(Pt 6), 1011-1022.
113. Pedersen, S. B.; Ølholm, J.; Paulsen, S. K.; Bennetzen, M. F.; Richelsen, B. Low Sirt1 expression, which is upregulated by fasting, in human adipose tissue from obese women. Int. J. Obes., 2008, 32(8), 1250-1255.
114. Bo, S.; Ciccone, G.; Castiglione, A.; Gambino, R.; De Michieli, F.; Villois, P.; Durazzo, M.; Cavallo-Perin, P.; Cassader, M. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr. Med. Chem., 2013, 20(10), 1323-1331.
115. Timmers, S.; Konings, E.; Bilet, L.; Houtkooper, R. H.; Van De Weijer, T.; Goossens, G. H.; Hoeks, J.; Van Der Krieken, S.; Ryu, D.; Kersten, S.; Moonen-Kornips, E.; Hesselink, M. K.; Kunz, I.; Schrauwen-Hinderling, V. B.; Blaak, E. E.; Auwerx, J.; Schrauwen, P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab., 2011, 14(5), 612-622.
116. Tomé-Carneiro, J.; Gonzálvez, M.; Larrosa, M.; Yáñez-Gascón, M. J.; García-Almagro, F. J.; Ruiz-Ros, J. A.; García-Conesa, M. T.; Tomás-Barberán, F. A.; Espín, J. C. Oneyear consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am. J. Cardiol., 2012, 110(3), 356-363.
117. Tomé-Carneiro, J.; Larrosa, M.; Yáñez-Gascón, M. J.; Dávalos, A.; Gil-Zamorano, J.; Gonzálvez, M.; García-Almagro, F. J.; Ruiz Ros, J. A.; Tomás-Barberán, F. A.; Espín, J. C.; García-Conesa, M. T. One-year supplementation with a grape extract containing resveratrol modulates inflammatoryrelated microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol. Res., 2013, 72, 69-82.
118. Agarwal, B.; Campen, M. J.; Channell, M. M.; Wherry, S. J.; Varamini, B.; Davis, J. G.; Baur, J. A.; Smoliga, J. M. Resveratrol for primary prevention of atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium. Int. J. Cardiol., 2013, 166(1), 246-248.
119. Poulsen, M. M.; Vestergaard, P. F.; Clasen, B. F.; Radko, Y.; Christensen, L. P.; Stødkilde-Jørgensen, H.; Møller, N.; Jessen, N.; Pedersen, S. B.; Jørgensen, J. O. High-dose resvera trol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes, 2013, 62(4), 1186-1195.
120. Ghanim, H.; Sia, C. L.; Abuaysheh, S.; Korzeniewski, K.; Patnaik, P.; Marumganti, A.; Chaudhuri, A.; Dandona, P. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J. Clin. Endocrinol. Metab., 2010, 95(9), E1-E8.
121. McAnulty, L. S.; Miller, L. E.; Hosick, P. A.; Utter, A. C.; Quindry, J. C.; McAnulty, S. R. Effect of resveratrol and quercetin supplementation on redox status and inflammation after exercise. Appl. Physiol. Nutr. Metab., 2013, 38(7), 760-765.
122. Laupheimer, M. W.; Perry, M.; Benton, S.; Malliaras, P.; Maffulli, N. Resveratrol exerts no effect on inflammatory response and delayed onset muscle soreness after a marathon in male athletes.: A randomised, double-blind, placebocontrolled pilot feasibility study. Transl. Med. UniSa, 2014, 10, 38-42.
123. Voduc, N.; La Porte, C.; Tessier, C.; Mallick, R.; Cameron, D. W. Effect of resveratrol on exercise capacity: a randomized placebo-controlled crossover pilot study. Appl. Physiol. Nutr. Metab., 2014, 39(10), 1183-1187.
124. Amri, A.; Chaumeil, J. C.; Sfar, S.; Charrueau, C. AAdministration of resveratrol: What formulation solutions to bioavailability limitations? J. Control. Release, 2012, 158(2), 182-193.
125. Walle, T.; Hsieh, F.; DeLegge, M. H.; Oatis, J. E., Jr; Walle, U. K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos., 2004, 32(12), 1377-1382.
126. Hoshino, J.; Park, E. J.; Kondratyuk, T. P.; Marler, L.; Pezzuto, J. M.; Van Breemen, R. B.; Mo, S.; Li, Y.; Cushman, M. Selective synthesis and biological evaluation of sulfateconjugated resveratrol metabolites. J. Med. Chem., 2010, 53(13), 5033-5043.
127. Calamini, B.; Ratia, K.; Malkowski, M. G.; Cuendet, M.; Pezzuto, J. M.; Santarsiero, B. D.; Mesecar, A. D. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem. J., 2010, 429(2), 273-282.
128. Jang, M.; Cai, L.; Udeani, G. O.; Slowing, K. V.; Thomas, C. F.; Beecher, C. W.; Fong, H. H.; Farnsworth, N. R.; Kinghorn, A. D.; Mehta, R. G.; Moon, R. C.; Pezzuto, J. M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 1997, 275(5297), 218-220.
129. Vitrac, X.; Desmouliere, A.; Brouillaud, B.; Krisa, S.; Deffieux, G.; Barthe, N.; Rosenbaum, J.; Merillon, J. M. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci., 2003, 72(20), 2219-2233.
130. Wenzel, E.; Soldo, T.; Erbersdobler, H.; Somoza, V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol. Nutr. Food Res., 2005, 49(5), 482-494.
131. Wenzel, E.; Somoza, V. Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res., 2005, 49(5), 472-481.
132. Andlauer, W.; Kolb, J.; Siebert, K.; Furst, P. Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp. Clin. Res., 2000, 26(2), 47-55.
133. Jose, S.; Anju, S. S.; Cinu, T. A.; Aleykutty, N. A.; Thomas, S.; Souto, E. B. In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery. Int. J. Pharm., 2014, 474(1-2), 6-13.
134. Summerlin, N.; Soo, E.; Thakur, S.; Qu, Z.; Jambhrunkar, S.; Popat, A. Resveratrol nanoformulations: challenges and opportunities. Int. J. Pharm., 2015, 479(2), 282-290.
135. Chauhan, A. S. Dendrimer nanotechnology for enhanced formulation and controlled delivery of resveratrol. Ann. N. Y. Acad. Sci,. 2015, 1348(1), 134-140.
136. Frozza, R. L.; Bernardi, A.; Hoppe, J. B.; Meneghetti, A. B.; Battastini, A. M.; Pohlmann, A. R.; Guterres, S. S.; Salbego, C. Lipid-core nanocapsules improve the effects of resveratrol against Abeta-induced neuroinflammation. J. Biomed. Nanotechnol., 2013, 9(12), 2086-2104.
137. Augustin, M. A.; Sanguansri, L.; Lockett, T. Nano- and micro-encapsulated systems for enhancing the delivery of resveratrol. Ann. N. Y. Acad. Sci., 2013, 1290, 107-112.
138. Neves, A. R.; Lucio, M.; Lima, J. L.; Reis, S. Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions. Curr. Med. Chem., 2012, 19(11), 1663-1681.
139. Santos, A. C.; Veiga, F.; Ribeiro, A. J. New delivery systems to improve the bioavailability of resveratrol. Expert Opin. Drug Deliv., 2011, 8(8), 973-990.
140. Li, C.; Zhang, J.; Zu, Y. J.; Nie, S. F.; Cao, J.; Wang, Q.; Nie, S. P.; Deng, Z. Y.; Xie, M. Y.; Wang, S. Biocompatible and biodegradable nanoparticles for enhancement of anticancer activities of phytochemicals. Chin. J. Nat. Med., 2015, 13(9), 641-652.
141. Coradini, K.; Lima, F. O.; Oliveira, C. M.; Chaves, P. S.; Athayde, M. L.; Carvalho, L. M.; Beck, R. C. Coencapsulation of resveratrol and curcumin in lipid-core nanocapsules improves their in vitro antioxidant effects. Eur. J. Pharm. Biopharm., 2014, 88(1), 178-185.
142. Joraholmen, M. W.; Skalko-Basnet, N.; Acharya, G.; Basnet, P. Resveratrol-loaded liposomes for topical treatment of the vaginal inflammation and infections. Eur. J. Pharm. Sci., 2015, 79, 112-121.
143. Cho, A. R.; Chun, Y. G.; Kim, B. K.; Park, D. J. Preparation of chitosan-TPP microspheres as resveratrol carriers. J. Food Sci., 2014, 79(4), E568-E576.
144. Biasutto, L.; Zoratti, M. Prodrugs of quercetin and resveratrol: a strategy under development. Curr. Drug Metab., 2014, 15(1), 77-95.
145. Hakkinen, S. H.; Karenlampi, S. O.; Heinonen, I. M.; Mykkanen, H. M.; Torronen, A. R. Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J. Agric. Food Chem., 1999, 47(6), 2274-2279.
146. Bischoff, S. C. Quercetin: potentials in the prevention and therapy of disease. Curr. Opin. Clin. Nutr. Metab. Care, 2008, 11(6), 733-740.
147. Boots, A. W.; Haenen, G. R.; Bast, A. Health effects of quercetin: from antioxidant to nutraceutical. Eur. J. Pharmacol., 2008, 585(2-3), 325-337.
148. Tu, B.; Liu, Z.-J.; Chen, Z.-F.; Ouyang, Y.; Hu, Y.-J. Understanding the structure-activity relationship between quercetin and naringenin: in vitro. RSC Advances, 2015, 5(128), 106171-106181.
149. Xiao, Z. P.; Wang, X. D.; Peng, Z. Y.; Huang, S.; Yang, P.; Li, Q. S.; Zhou, L. H.; Hu, X. J.; Wu, L. J.; Zhou, Y.; Zhu, H. L. Molecular docking, kinetics study, and structureactivity relationship analysis of quercetin and its analogous as Helicobacter pylori urease inhibitors. J. Agric. Food Chem., 2012, 60(42), 10572-10577.
150. Mrvová, N.; Škandík, M.; Kuniaková, M.; Račková, L. Modulation of BV-2 microglia functions by novel quercetin pivaloyl ester. Neurochem. Int., 2015, 90, 246-254.
151. Milackova, I.; Prnova, M. S.; Majekova, M.; Sotnikova, R.; Stasko, M.; Kovacikova, L.; Banerjee, S.; Veverka, M.; Stefek, M. 2-Chloro-1, 4-naphthoquinone derivative of quercetin as an inhibitor of aldose reductase and anti inflammatory agent. J. Enzyme Inhib. Med. Chem., 2015, 30(1), 107-113.
152. Ortega, M. G.; Saragusti, A. C.; Cabrera, J. L.; Chiabrando, G. A. Quercetin tetraacetyl derivative inhibits LPS-induced nitric oxide synthase (iNOS) expression in J774A.1 cells. Arch. Biochem. Biophys., 2010, 498(2), 105-110.
153. Zhong, D.; Liu, M.; Cao, Y.; Zhu, Y.; Bian, S.; Zhou, J.; Wu, F.; Ryu, K. C.; Zhou, L.; Ye, D. Discovery of metal ions chelator quercetin derivatives with potent anti-HCV activities. Molecules, 2015, 20(4), 6978-6999.
154. Park, E. J.; Kim, J. Y.; Jeong, M. S.; Park, K. Y.; Park, K. H.; Lee, M. W.; Joo, S. S.; Seo, S. J. Effect of topical application of quercetin-3-O-(2"-gallate)-α-l-rhamnopyranoside on atopic dermatitis in NC/Nga mice. J. Dermatol. Sci., 2015, 77(3), 166-172.
155. Lee, C. S.; Jeong, E. B.; Kim, Y. J.; Lee, M. S.; Seo, S. J.; Park, K. H.; Lee, M. W. Quercetin-3-O-(2"-galloyl)-α-lrhamnopyranoside inhibits TNF-α-activated NF-κBinduced inflammatory mediator production by suppressing ERK activation. Int. Immunopharmacol., 2013, 16(4), 481-487.
156. Kim, Y. J.; Jung, E. B.; Seo, S. J.; Park, K. H.; Lee, M. W.; Lee, C. S. Quercetin-3-O-(2"-galloyl)-α-l-rhamnopyranoside prevents TRAIL-induced apoptosis in human keratinocytes by suppressing the caspase-8- and Bid-pathways and the mitochondrial pathway. Chem. Biol. Interact., 2013, 204(3), 144-152.
157. Ying, H. Z.; Zang, J. N.; Deng, L. L.; Wang, Z. Y.; Yu, C. H. Pentamethylquercetin reduces fat deposition via Sirt1-mediated pathways in male obese mice induced by a high fat diet. Food Chem. Toxicol., 2013, 62, 463-469.
158. Chang, Y. C.; Tsai, M. H.; Sheu, W. H.; Hsieh, S. C.; Chiang, A. N. The therapeutic potential and mechanisms of action of quercetin in relation to lipopolysaccharide-induced sepsis in vitro and in vivo. PLoS One, 2013, 8(11), e80744.
159. Liao, Y. R.; Lin, J. Y. Quercetin intraperitoneal administration ameliorates lipopolysaccharide-induced systemic inflammation in mice. Life Sci., 2015, 137, 89-97.
160. Sekhon-Loodu, S.; Ziaullah, Z.; Rupasinghe, H. P.; Wang, Y.; Kulka, M.; Shahidi, F. Novel quercetin-3-O-glucoside eicosapentaenoic acid ester ameliorates inflammation and hyperlipidemia. Inflammopharmacology, 2015, 23(4), 173-185.
161. Oliveira, T. T.; Campos, K. M.; Cerqueira-Lima, A. T.; Cana Brasil Carneiro, T.; Da Silva Velozo, E.; Ribeiro Melo, I. C.; Figueiredo, E. A.; De Jesus Oliveira, E.; De Vasconcelos, D. F.; Pontes-De-Carvalho, L. C.; Alcantara-Neves, N. M.; Figueiredo, C. A. Potential therapeutic effect of Allium cepa L. and quercetin in a murine model of Blomia tropicalis induced asthma. Daru, 2015, 23, 18.
162. Yang, T.; Luo, F.; Shen, Y.; An, J.; Li, X.; Liu, X.; Ying, B.; Liao, Z.; Dong, J.; Guo, L.; Wang, T.; Xu, D.; Chen, L.; Wen, F. Quercetin attenuates airway inflammation and mucus production induced by cigarette smoke in rats. Int. Immunopharmacol., 2012, 13(1), 73-81.
163. Carlsen, I.; Frokiar, J.; Norregaard, R. Quercetin attenuates cyclooxygenase-2 expression in response to acute ureteral obstruction. Am. J. Physiol. Renal Physiol., 2015, 308(11), F1297-F1305.
164. Pisonero-Vaquero, S.; Martinez-Ferreras, A.; Garcia-Mediavilla, M. V.; Martinez-Florez, S.; Fernandez, A.; Benet, M.; Olcoz, J. L.; Jover, R.; Gonzalez-Gallego, J.; Sanchez-Campos, S. Quercetin ameliorates dysregulation of lipid metabolism genes via the PI3K/AKT pathway in a diet-induced mouse model of nonalcoholic fatty liver disease. Mol. Nutr. Food Res., 2015, 59(5), 879-893.
165. Ishisaka, A.; Kawabata, K.; Miki, S.; Shiba, Y.; Minekawa, S.; Nishikawa, T.; Mukai, R.; Terao, J.; Kawai, Y. Mitochondrial dysfunction leads to deconjugation of quercetin glucuronides in inflammatory macrophages. PLoS One, 2013, 8(11), e80843.
166. Bhaskar, S.; Kumar, K. S.; Krishnan, K.; Antony, H. Quercetin alleviates hypercholesterolemic diet induced inflammation during progression and regression of atherosclerosis in rabbits. Nutrition, 2013, 29(1), 219-229.
167. Chan, S. T.; Chuang, C. H.; Yeh, C. L.; Liao, J. W.; Liu, K. L.; Tseng, M. J.; Yeh, S. L. Quercetin supplementation suppresses the secretion of pro-inflammatory cytokines in the lungs of Mongolian gerbils and in A549 cells exposed to benzo[a]pyrene alone or in combination with β-carotene: in vivo and ex vivo studies. J. Nutr. Biochem., 2012, 23(2), 179-185.
168. Ganesan, S.; Faris, A. N.; Comstock, A. T.; Chattoraj, S. S.; Chattoraj, A.; Burgess, J. R.; Curtis, J. L.; Martinez, F. J.; Zick, S.; Hershenson, M. B.; Sajjan, U. S. Quercetin prevents progression of disease in elastase/LPS-exposed mice by negatively regulating MMP expression. Respir. Res., 2010, 11, 131.
169. Gonzalez-Segovia, R.; Quintanar, J. L.; Salinas, E.; Ceballos-Salazar, R.; Aviles-Jimenez, F.; Torres-Lopez, J. Effect of the flavonoid quercetin on inflammation and lipid peroxidation induced by Helicobacter pylori in gastric mucosa of guinea pig. J. Gastroenterol., 2008, 43(6), 441-447.
170. De Boer, V. C.; Dihal, A. A.; Van Der Woude, H.; Arts, I. C.; Wolffram, S.; Alink, G. M.; Rietjens, I. M.; Keijer, J.; Hollman, P. C. Tissue distribution of quercetin in rats and pigs. J. Nutr., 2005, 135(7), 1718-1725.
171. Wang, S.; Su, R.; Nie, S.; Sun, M.; Zhang, J.; Wu, D.; Moustaid-Moussa, N. Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals. J. Nutr. Biochem., 2014, 25(4), 363-376.
172. Tan, B. J.; Liu, Y.; Chang, K. L.; Lim, B. K.; Chiu, G. N. Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer. Int. J. Nanomedicine, 2012, 7, 651-661.
173. Rajasekaran, M.; Annaraj, J. A lucid build-up of nanostructured curcumin, quercetin and their interaction with. DNA Naanosci. Nanotechnol., 2014, 14(7), 4874-4879.
174. Hadrich, G.; Monteiro, S. O.; Rodrigues, M. R.; De Lima, V. R.; Putaux, J. L.; Bidone, J.; Teixeira, H. F.; Muccillo-Baisch, A. L.; Dora, C. L. Lipid-based nanocarrier for quercetin delivery: system characterization and molecular interactions studies. Drug Dev. Ind. Pharm., 2016, 42(7), 1165-1173.
175. Sun, M.; Nie, S.; Pan, X.; Zhang, R.; Fan, Z.; Wang, S. Quercetin-nanostructured lipid carriers: characteristics and anti-breast cancer activities in vitro. Colloids Surf. B Biointerfaces, 2014, 113, 15-24.
176. Chen-Yu, G.; Chun-Fen, Y.; Qi-Lu, L.; Qi, T.; Yan-Wei, X.; Wei-Na, L.; Guang-Xi, Z. Development of a quercetinloaded nanostructured lipid carrier formulation for topical delivery. Int. J. Pharm., 2012, 430(1-2), 292-298.
177. Xu, G.; Shi, H.; Ren, L.; Gou, H.; Gong, D.; Gao, X.; Huang, N. Enhancing the anti-colon cancer activity of quercetin by self-assembled micelles. Int. J. Nanomedicine, 2015, 10, 2051-2063.
178. Chitkara, D.; Nikalaje, S. K.; Mittal, A.; Chand, M.; Kumar, N. Development of quercetin nanoformulation and in vivo evaluation using streptozotocin induced diabetic rat model. Drug Deliv. Transl. Res., 2012, 2(2), 112-123.
179. Bagad, M.; Khan, Z. A. Poly (n-butylcyanoacrylate) nanoparticles for oral delivery of quercetin: preparation, characterization, and pharmacokinetics and biodistribution studies in Wistar rats. Int. J. Nanomedicine, 2015, 10, 3921-3935.
180. Rezaei-Sadabady, R.; Eidi, A.; Zarghami, N.; Barzegar, A. Intracellular ROS protection efficiency and free radicalscavenging activity of quercetin and quercetin-encapsulated liposomes. Artif. Cells Nanomed. Biotechnol., 2016, 44(1), 128-134.
181. Gulec, K.; Demirel, M. Characterization and antioxidant activity of quercetin/methyl-b-cyclodextrin complexes. Curr. Drug Deliv., 2015, [Epub ahead of Print].
182. Du, H.; Liu, M.; Yang, X.; Zhai, G. The role of glycyrrhetinic acid modification on preparation and evaluation of quercetin-loaded chitosan-based self-aggregates. J. Colloid Interface Sci., 2015, 460, 87-96.
183. Mukai, R.; Fujikura, Y.; Murota, K.; Uehara, M.; Minekawa, S.; Matsui, N.; Kawamura, T.; Nemoto, H.; Terao, J. Prenylation enhances quercetin uptake and reduces efflux in Caco-2 cells and enhances tissue accumulation in mice fed long-term. J. Nutr., 2013, 143(10), 1558-1564.
184. Hsu, C. H.; Cheng, A. L. Clinical studies with curcumin. Adv. Exp. Med. Biol., 2007, 595, 471-480.
185. Bhullar, K. S.; Jha, A.; Youssef, D.; Rupasinghe, H. P. Curcumin and its carbocyclic analogs: structure-activity in relation to antioxidant and selected biological properties. Molecules, 2013, 18(5), 5389-5404.
186. Anand, P.; Sung, B.; Kunnumakkara, A. B.; Rajasekharan, K. N.; Aggarwal, B. B. Suppression of pro-inflammatory and proliferative pathways by diferuloylmethane (curcumin) and its analogues dibenzoylmethane, dibenzoylpropane, and dibenzylideneacetone: role of Michael acceptors and Michael donors. Biochem. Pharmacol., 2011, 82(12), 1901-1909.
187. Liang, G.; Shao, L.; Wang, Y.; Zhao, C.; Chu, Y.; Xiao, J.; Zhao, Y.; Li, X.; Yang, S. Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg. Med. Chem., 2009, 17(6), 2623-2631.
188. Pan, Y.; Wang, Y.; Zhao, Y.; Peng, K.; Li, W.; Wang, Y.; Zhang, J.; Zhou, S.; Liu, Q.; Li, X.; Cai, L.; Liang, G. Inhibition of JNK phosphorylation by a novel curcumin analog prevents high glucose-induced inflammation and apoptosis in cardiomyocytes and the development of diabetic cardiomyopathy. Diabetes, 2014, 63(10), 3497
189. Pan, Y.; Wang, Y.; Cai, L.; Cai, Y.; Hu, J.; Yu, C.; Li, J.; Feng, Z.; Yang, S.; Li, X.; Liang, G. Inhibition of high glucoseinduced inflammatory response and macrophage infiltration by a novel curcumin derivative prevents renal injury in diabetic rats. Br. J. Pharmacol., 2012, 166(3), 1169-1182.
190. Pan, Y.; Zhu, G.; Wang, Y.; Cai, L.; Cai, Y.; Hu, J.; Li, Y.; Yan, Y.; Wang, Z.; Li, X.; Wei, T.; Liang, G. Attenuation of high-glucose-induced inflammatory response by a novel curcumin derivative B06 contributes to its protection from diabetic pathogenic changes in rat kidney and heart. J. Nutr. Biochem., 2013, 24(1), 146-155.
191. Narumoto, O.; Matsuo, Y.; Sakaguchi, M.; Shoji, S.; Yamashita, N.; Schubert, D.; Abe, K.; Horiguchi, K.; Nagase, T.; Yamashita, N. Suppressive effects of a pyrazole derivative of curcumin on airway inflammation and remodeling. Exp. Mol. Pathol., 2012, 93(1), 18-25.
192. Jayaraj, R. L.; Elangovan, N.; Dhanalakshmi, C.; Manivasagam, T.; Essa, M. M. CNB-001, a novel pyrazole derivative mitigates motor impairments associated with neurodegeneration via suppression of neuroinflammatory and apoptotic response in experimental Parkinson's disease mice. Chem. Biol. Interact., 2014, 220, 149-157.
193. Lee, K. H.; Chow, Y. L.; Sharmili, V.; Abas, F.; Alitheen, N. B.; Shaari, K.; Israf, D. A.; Lajis, N. H.; Syahida, A. BDMC33, A curcumin derivative suppresses inflammatory responses in macrophage-like cellular system: role of inhibition in NF-κB and MAPK signaling pathways. Int. J. Mol. Sci., 2012, 13(3), 2985-3008.
194. Yuan, S.; Cao, S.; Jiang, R.; Liu, R.; Bai, J.; Hou, Q. FLLL31, a derivative of curcumin, attenuates airway inflammation in a multi-allergen challenged mouse model. Int. Immunopharmacol., 2014, 21(1), 128-136.
195. Tham, C. L.; Liew, C. Y.; Lam, K. W.; Mohamad, A. S.; Kim, M. K.; Cheah, Y. K.; Zakaria, Z. A.; Sulaiman, M. R.; Lajis, N. H.; Israf, D. A. A synthetic curcuminoid derivative inhibits nitric oxide and proinflammatory cytokine synthesis. Eur. J. Pharmacol., 2010, 628(1-3), 247-254.
196. Katsori, A. M.; Palagani, A.; Bougarne, N.; Hadjipavlou-Litina, D.; Haegeman, G.; Vanden Berghe, W. Inhibition of the NF-κB signaling pathway by a novel heterocyclic curcumin analogue. Molecules, 2015, 20(1), 863-878.
197. Wang, Y.; Yu, C.; Pan, Y.; Yang, X.; Huang, Y.; Feng, Z.; Li, X.; Yang, S.; Liang, G. A novel synthetic monocarbonyl analogue of curcumin, A13, exhibits antiinflammatory effects in vivo by inhibition of inflammatory mediators. Inflammation, 2012, 35(2), 594-604.
198. Liu, L.; Shang, Y.; Li, M.; Han, X.; Wang, J.; Wang, J. Curcumin ameliorates asthmatic airway inflammation by activating nuclear factor-E2-related factor 2/haem oxygenase (HO)-1 signalling pathway. Clin. Exp. Pharmacol. Physiol., 2015, 42(5), 520-529.
199. Ma, C.; Ma, Z.; Fu, Q.; Ma, S. Curcumin attenuates allergic airway inflammation by regulation of CD4+CD25+ regulatory T cells (Tregs)/Th17 balance in ovalbumin-sensitized mice. Fitoterapia, 2013, 87, 57-64.
200. Ghosh, S. S.; Gehr, T. W.; Ghosh, S. Curcumin and chronic kidney disease (CKD): major mode of action through stimulating endogenous intestinal alkaline phosphatase. Molecules, 2014, 19(12), 20139-20156.
201. Ghosh, S. S.; Krieg, R.; Massey, H. D.; Sica, D. A.; Fakhry, I.; Ghosh, S.; Gehr, T. W. Curcumin and enalapril ameliorate renal failure by antagonizing inflammation in 5/6 nephrectomized rats: role of phospholipase and cyclooxygenase. Am. J. Physiol. Renal Physiol., 2012, 302(4), F439-F454.
202. Zeng, C.; Zhong, P.; Zhao, Y.; Kanchana, K.; Zhang, Y.; Khan, Z. A.; Chakrabarti, S.; Wu, L.; Wang, J.; Liang, G. Curcumin protects hearts from FFA-induced injury by activating Nrf2 and inactivating NF-κB both in vitro and in vivo. J. Mol. Cell. Cardiol., 2015, 79, 1-12.
203. Deng, Z. H.; Liao, J.; Zhang, J. Y.; Hao, X. H.; Liang, C.; Wang, L. H.; Xue, H.; Zhang, K.; Yan, G. T. Localized leptin release may be an important mechanism of curcumin action after acute ischemic injuries. J. Trauma Acute Care Surg., 2013, 74(4), 1044-1051.
204. Yuan, Z.; Syed, M. A.; Panchal, D.; Rogers, D.; Joo, M.; Sadikot, R. T. Curcumin mediated epigenetic modulation inhibits TREM-1 expression in response to lipopolysaccharide. Int. J. Biochem. Cell Biol., 2012, 44(11), 2032-2043.
205. Wang, M. E.; Chen, Y. C.; Chen, I. S.; Hsieh, S. C.; Chen, S. S.; Chiu, C. H. Curcumin protects against thioacetamideinduced hepatic fibrosis by attenuating the inflammatory response and inducing apoptosis of damaged hepatocytes. J. Nutr. Biochem., 2012, 23(10), 1352-1366.
206. Beloqui, A.; Coco, R.; Memvanga, P. B.; Ucakar, B.; Des Rieux, A.; Preat, V. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Int. J. Pharm., 2014, 473(1-2), 203-212.
207. Yen, F. L.; Tsai, M. H.; Yang, C. M.; Liang, C. J.; Lin, C. C.; Chiang, Y. C.; Lee, H. C.; Ko, H. H.; Lee, C. W. Curcumin nanoparticles ameliorate ICAM-1 expression in TNF-α-treated lung epithelial cells through p47 (phox) and MAPKs/AP-1 pathways. PLoS One, 2013, 8(5), e63845.
208. Lin, Y. H.; Lin, J. H.; Hong, Y. S. Development of chitosan/poly-γ-glutamic acid/pluronic/curcumin nanoparticles in chitosan dressings for wound regeneration. J. Biomed. Mater. Res. B Appl. Biomater., 2015.
209. Manca, M. L.; Castangia, I.; Zaru, M.; Nacher, A.; Valenti, D.; Fernandez-Busquets, X.; Fadda, A. M.; Manconi, M. Development of curcumin loaded sodium hyaluronate immobilized vesicles (hyalurosomes) and their potential on skin inflammation and wound restoring. Biomaterials, 2015, 71, 100-109.
210. Schaffer, M.; Schaffer, P. M.; Bar-Sela, G. An update on Curcuma as a functional food in the control of cancer and inflammation. Curr. Opin. Clin. Nutr. Metab. Care, 2015, 18(6), 605-611.
211. Jeenger, M. K.; Shrivastava, S.; Yerra, V. G.; Naidu, V. G.; Ramakrishna, S.; Kumar, A. Curcumin: a pleiotropic phytonutrient in diabetic complications. Nutrition, 2015, 31(2), 276-282.
212. Zhou, H.; Beevers, C. S.; Huang, S. The targets of curcumin. Curr. Drug Targets, 2011, 12(3), 332-347.
213. Srivastava, R. M.; Singh, S.; Dubey, S. K.; Misra, K.; Khar, A. Immunomodulatory and therapeutic activity of Intcurcumin. Immunopharmacol., 2011, 11(3), 331-341.
214. Shehzad, A.; Rehman, G.; Lee, Y. S. Curcumin in inflammatory diseases. Biofactors, 2013, 39(1), 69-77.
215. Anand, P.; Kunnumakkara, A. B.; Newman, R. A.; Aggarwal, B. B. Bioavailability of curcumin: problems and promises. Mol. Pharm., 2007, 4(6), 807-818.
216. Cheng, A. L.; Hsu, C. H.; Lin, J. K.; Hsu, M. M.; Ho, Y. F.; Shen, T. S.; Ko, J. Y.; Lin, J. T.; Lin, B. R.; Ming-Shiang, W.; Yu, H. S.; Jee, S. H.; Chen, G. S.; Chen, T. M.; Chen, C. A.; Lai, M. K.; Pu, Y. S.; Pan, M. H.; Wang, Y. J.; Tsai, C. C.; Hsieh, C. Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res., 2001, 21(4B), 2895-2900.
217. Ireson, C.; Orr, S.; Jones, D. J.; Verschoyle, R.; Lim, C. K.; Luo, J. L.; Howells, L.; Plummer, S.; Jukes, R.; Williams, M.; Steward, W. P.; Gescher, A. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res., 2001, 61(3), 1058-1064.
218. Sharma, R. A.; Euden, S. A.; Platton, S. L.; Cooke, D. N.; Shafayat, A.; Hewitt, H. R.; Marczylo, T. H.; Morgan, B.; Hemingway, D.; Plummer, S. M.; Pirmohamed, M.; Gescher, A. J.; Steward, W. P. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res., 2004, 10(20), 6847-6854.
219. Kumar, S.; Kesharwani, S. S.; Mathur, H.; Tyagi, M.; Bhat, G. J.; Tummala, H. Molecular complexation of curcumin with pH sensitive cationic copolymer enhances the aqueous solubility, stability and bioavailability of curcumin Eur. J. Pharm. Sci., 2015, 82, 86-96.
220. Wang, C.; Ma, C.; Wu, Z.; Liang, H.; Yan, P.; Song, J.; Ma, N.; Zhao, Q. Enhanced bioavailability and anticancer effect of curcumin-loaded electrospun nanofiber: in vitro and in vivo study. Nanoscale Res. Lett., 2015, 10(1), 439.
221. Nasrolahi Shirazi, A.; El-Sayed, N. S.; Tiwari, R. K.; Tavakoli, K.; Parang, K. Cyclic peptide containing hydrophobic and positively charged residues as a drug delivery system for curcumin. Curr. Drug Deliv., 2015.
222. Sarika, P. R.; James, N. R.; Kumar, P. R.; Raj, D. K.; Kumary, T. V. Gum arabic-curcumin conjugate micelles with enhanced loading for curcumin delivery to hepatocarcinoma cells. Carbohydr. Polym., 2015, 134, 167-174.
223. Gao, M.; Chen, C.; Fan, A.; Zhang, J.; Kong, D.; Wang, Z.; Zhao, Y. Covalent and non-covalent curcumin loading in acid-responsive polymeric micellar nanocarriers. Nanotechnology, 2015, 26(27), 275101.
224. Wang, Z.; Chen, C.; Zhang, Q.; Gao, M.; Zhang, J.; Kong, D.; Zhao, Y. Tuning the architecture of polymeric conjugate to mediate intracellular delivery of pleiotropic curcumin. Eur. J. Pharm. Biopharm., 2015, 90, 53-62.
225. Pan, K.; Luo, Y.; Gan, Y.; Baek, S. J.; Zhong, Q. pH-driven encapsulation of curcumin in self-assembled casein nanoparticles for enhanced dispersibility and bioactivity. Soft Matter., 2014, 10(35), 6820-6830.
226. Peng, S.; Hung, W. L.; Peng, Y. S.; Chu, I. M. Oligoalaninemodified Pluronic-F127 nanocarriers for the delivery of curcumin with enhanced entrapment efficiency. J. Biomater. Sci. Polym. Ed., 2014, 25(12), 1225-1239.
227. Ramalingam, P.; Ko, Y. T. Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations. Pharm. Res., 2015, 32(2), 389-402.
228. Zupančič, Š; Kocbek, P.; Zariwala, M. G.; Renshaw, D.; Gul, M. O.; Elsaid, Z.; Taylor, K. M.; Somavarapu, S. Design and development of novel mitochondrial targeted nanocarriers, DQAsomes for curcumin inhalation. Mol. Pharm., 2014, 11(7), 2334-2345.
229. Hu, L.; Kong, D.; Hu, Q.; Gao, N.; Pang, S. Evaluation of high-performance curcumin nanocrystals for pulmonary drug delivery both in vitro and in vivo. Nanoscale Res. Lett., 2015, 10(1), 381.
230. Sareen, R.; Jain, N.; Dhar, K. L. Curcumin-Zn (II) complex for enhanced solubility and stability: an approach for improved delivery and pharmacodynamic effects. Pharm. Dev. Technol., 2015, 21(5), 630-635.
231. Liang, J.; Wu, W.; Lai, D.; Li, J.; Fang, C. Enhanced solubility and targeted delivery of curcumin by lipopeptide micelles. J. Biomater. Sci. Polym. Ed., 2015, 26(6), 369-383.
232. Zhu, W.; Song, Z.; Wei, P.; Meng, N.; Teng, F.; Yang, F.; Liu, N.; Feng, R. Y-shaped biotin-conjugated poly (ethylene glycol)-poly (epsilon-caprolactone) copolymer for the targeted delivery of curcumin. J. Colloid Interface Sci., 2015, 443, 1-7.
233. Lee, W. H.; Loo, C. Y.; Young, P. M.; Traini, D.; Mason, R. S.; Rohanizadeh, R. Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin. Drug Deliv., 2014, 11(8), 1183-1201.
234. Shehzad, A.; Ul-Islam, M.; Wahid, F.; Lee, Y. S. Multifunctional polymeric nanocurcumin for cancer therapy. J. Nanosci. Nanotechnol., 2014, 14(1), 803-814.
235. Huang, D. W.; Chang, W. C.; Wu, J. S.; Shih, R. W.; Shen, S. C. Gallic acid ameliorates hyperglycemia and improves hepatic carbohydrate metabolism in rats fed a high-fructose diet. Nutr. Res., 2016, 36(2), 150-160.
236. Ahad, A.; Ahsan, H.; Mujeeb, M.; Siddiqui, W. A. Gallic acid ameliorates renal functions by inhibiting the activation of p38 MAPK in experimentally induced type 2 diabetic rats and cultured rat proximal tubular epithelial cells. Chem. Biol. Interact., 2015, 240, 292-303.
237. Pandurangan, A. K.; Mohebali, N.; Mohd Esa, N.; Looi, C. Y.; Ismail, S.; Saadatdoust, Z. Gallic acid suppresses inflammation in dextran sodium sulfate-induced colitis in mice: Possible mechanisms. Int. Immunopharmacol., 2015, 28(2), 1034-1043.
238. Sarkaki, A.; Farbood, Y.; Gharib-Naseri, M. K.; Badavi, M.; Mansouri, M. T.; Haghparast, A.; Mirshekar, M. A. Gallic acid improved behavior, brain electrophysiology, and inflammation in a rat model of traumatic brain injury. Can. J. Physiol. Pharmacol., 2015, 93(8), 687-694.
239. Chang, W. C.; Wu, J. S.; Chen, C. W.; Kuo, P. L.; Chien, H. M.; Wang, Y. T.; Shen, S. C. Protective effect of vanillic acid against hyperinsulinemia, hyperglycemia and hyperlip idemia via alleviating hepatic insulin resistance and inflammation in high-fat diet (HFD) - fed rats. Nutrients, 2015, 7(12), 9946-9959.
240. Yrbas, M. L.; Morucci, F.; Alonso, R.; Gorzalczany, S. Pharmacological mechanism underlying the antinociceptive activity of vanillic acid. Pharmacol. Biochem. Behav., 2015, 132, 88-95.
241. Calixto-Campos, C.; Carvalho, T. T.; Hohmann, M. S.; Pinho-Ribeiro, F. A.; Fattori, V.; Manchope, M. F.; Zarpelon, A. C.; Baracat, M. M.; Georgetti, S. R.; Casagrande, R.; Verri, W. A., Jr Vanillic acid inhibits inflammatory pain by inhibiting neutrophil recruitment, oxidative stress, cytokine production, and nfκb activation in mice. J. Nat. Prod., 2015, 78(8), 1799-1808.
242. Yagi, K. [Liver protective effect of Lentinula edodes mycelia (LEM)]. Gan To Kagaku Ryoho, 2012, 39(7), 1099-1102.
243. Tokmak, M.; Yuksel, Y.; Sehitoglu, M. H.; Guven, M.; Akman, T.; Aras, A. B.; Cosar, M.; Abbed, K. M. The neuroprotective effect of syringic acid on spinal cord ischemia/reperfusion injury in rats. Inflammation, 2015, 38(5), 1969-1978.
244. Peiffer, D. S.; Wang, L. S.; Zimmerman, N. P.; Carmella, S. G.; Kuo, C. T.; Chen, J. H.; Oshima, K.; Huang, Y. W.; Hecht, S. S.; Stoner, G. Dietary consumption of black raspberries or their anthocyanin constituents alters innate immune cell trafficking in esophageal cancer. Cancer Immunol. Res., 2016, 4(11), 72-82.
245. Zhang, Z.; Li, G.; Szeto, S. S.; Chong, C. M.; Quan, Q.; Huang, C.; Cui, W.; Guo, B.; Wang, Y.; Han, Y.; Michael Siu, K. W.; Yuen Lee, S. M.; Chu, I. K. Examining the neuroprotective effects of protocatechuic acid and chrysin on in vitro and in vivo models of Parkinson disease. Free Radic. Biol. Med., 2015, 84, 331-343.
246. Wang, Y.; Zhou, J.; Fu, S.; Wang, C.; Zhou, B. Preventive effects of protocatechuic acid on LPS-induced inflammatory response in human gingival fibroblasts via activating PPAR-γ. Inflammation, 2015, 38(3), 1080-1084.
247. Song, Y.; Cui, T.; Xie, N.; Zhang, X.; Qian, Z.; Liu, J. Protocatechuic acid improves cognitive deficits and attenuates amyloid deposits, inflammatory response in aged AβPP/PS1 double transgenic mice. Int. Immunopharmacol., 2014, 20(1), 276-281.
248. Wei, M.; Chu, X.; Guan, M.; Yang, X.; Xie, X.; Liu, F.; Chen, C.; Deng, X. Protocatechuic acid suppresses ovalbumininduced airway inflammation in a mouse allergic asthma model. Int. Immunopharmacol., 2013, 15(4), 780-788.
249. Wei, M.; Chu, X.; Jiang, L.; Yang, X.; Cai, Q.; Zheng, C.; Ci, X.; Guan, M.; Liu, J.; Deng, X. Protocatechuic acid attenuates lipolysaccharide-induced acute lung injury. Inflammation, 2012, 35(3), 1169-1178.
250. Balupillai, A.; Prasad, R. N.; Ramasamy, K.; Muthusamy, G.; Shanmugham, M.; Govindasamy, K.; Gunaseelan, S. Caffeic acid inhibits UVB-induced inflammation and photocarcinogenesis through activation of peroxisome proliferatoractivated receptor-γ in mouse skin. Photochem. Photobiol., 2015, 91(6), 1458-1468.
251. Barlas, F. B.; Erdoǧan, S. Caffeic acid phenethyl ester protects lung alveolar epithelial cells from cigarette smokeinduced damage. Turk. J. Med. Sci., 2015, 45(3), 534-541.
252. Jeon, Y. D.; Kee, J. Y.; Kim, D. S.; Han, Y. H.; Kim, S. H.; Kim, S. J.; Um, J. Y.; Hong, S. H. Effects of Ixeris dentata water extract and caffeic acid on allergic inflammation in vivo and in vitro. BMC Complement. Altern. Med., 2015, 15, 196.
253. Pinheiro Fernandes, F. D.; Fontenele Menezes, A. P.; De Sousa Neves, J. C.; Fonteles, A. A.; Da Silva, A. T.; De Araujo Rodrigues, P.; Santos Do Carmo, M. R.; De Souza, C. M.; De Andrade, G. M. Caffeic acid protects mice from memory deficits induced by focal cerebral ischemia. Behav. Pharmacol., 2014, 25(7), 637-647.
254. Cheng, Y. T.; Ho, C. Y.; Jhang, J. J.; Lu, C. C.; Yen, G. C. DJ-1 plays an important role in caffeic acid-mediated protection of the gastrointestinal mucosa against ketoprofeninduced oxidative damage. J. Nutr. Biochem., 2014, 25(10), 1045-1057.
255. Liu, M.; Song, S.; Li, H.; Jiang, X.; Yin, P.; Wan, C.; Liu, X.; Liu, F.; Xu, J. The protective effect of caffeic acid against inflammation injury of primary bovine mammary epithelial cells induced by lipopolysaccharide. J. Dairy Sci., 2014, 97(5), 2856-2865.
256. Zhang, M.; Zhou, J.; Wang, L.; Li, B.; Guo, J.; Guan, X.; Han, Q.; Zhang, H. Caffeic acid reduces cutaneous tumor necrosis factor alpha (TNF-α), IL-6 and IL-1β levels and ameliorates skin edema in acute and chronic model of cutaneous inflammation in mice. Biol. Pharm. Bull., 2014, 37(3), 347-354.
257. Pragasam, S. J.; Rasool, M. Dietary component p-coumaric acid suppresses monosodium urate crystal-induced inflammation in rats. Inflamm. Res., 2013, 62(5), 489-498.
258. Pragasam, S. J.; Venkatesan, V.; Rasool, M. Immunomodulatory and anti-inflammatory effect of p-coumaric acid, a common dietary polyphenol on experimental inflammation in rats. Inflammation, 2013, 36(1), 169-176.
259. Lampiasi, N.; Montana, G. The molecular events behind ferulic acid mediated modulation of IL-6 expression in LPS-activated Raw 264.7 cells. Immunobiology, 2016, 221(3), 486-493.
260. Lee, C. C.; Wang, C. C.; Huang, H. M.; Lin, C. L.; Leu, S. J.; Lee, Y. L. Ferulic Acid Induces Th1 Responses by Modulating the Function of Dendritic Cells and Ameliorates Th2-Mediated Allergic Airway Inflammation in Mice. Evid.-Based Complement. Alternat. Med., 2015, 2015, 678487.
261. Tsai, C. Y.; Woung, L. C.; Yen, J. C.; Tseng, P. C.; Chiou, S. H.; Sung, Y. J.; Liu, K. T.; Cheng, Y. H. Thermosensitive chitosan-based hydrogels for sustained release of ferulic acid on corneal wound healing. Carbohydr. Polym., 2016, 135, 308-315.
262. Senaphan, K.; Kukongviriyapan, U.; Sangartit, W.; Pakdeechote, P.; Pannangpetch, P.; Prachaney, P.; Greenwald, S. E.; Kukongviriyapan, V. Ferulic acid alleviates changes in a rat model of metabolic syndrome induced by highcarbohydrate, high-fat diet. Nutrients, 2015, 7(8), 6446-6464.
263. Bacanli, M.; Aydin, S.; Taner, G.; Göktaş, H. G.; Şahin, T.; Başaran, A. A.; Başaran, N. The protective role of ferulic acid on sepsis-induced oxidative damage in Wistar albino rats. Environ. Toxicol. Pharmacol., 2014, 38(3), 774-782.
264. Das, U.; Manna, K.; Sinha, M.; Datta, S.; Das, D. K.; Chakraborty, A.; Ghosh, M.; Saha, K. D.; Dey, S. Role of ferulic acid in the amelioration of ionizing radiation induced inflammation: a murine model. PLoS One, 2014, 9(5), e97599.
265. Sung, J. H.; Gim, S. A.; Koh, P. O. Ferulic acid attenuates the cerebral ischemic injury-induced decrease in peroxiredoxin-2 and thioredoxin expression. Neurosci. Lett., 2014, 566, 88-92.
266. Shin, D. S.; Kim, K. W.; Chung, H. Y.; Yoon, S.; Moon, J. O. Effect of sinapic acid against carbon tetrachloride-induced acute hepatic injury in rats. Arch. Pharm. Res., 2013, 36(5), 626-633.
267. Yun, K. J.; Koh, D. J.; Kim, S. H.; Park, S. J.; Ryu, J. H.; Kim, D. G.; Lee, J. Y.; Lee, K. T. Anti-inflammatory effects of sinapic acid through the suppression of inducible nitric oxide synthase, cyclooxygase-2, and proinflammatory cytoki nes expressions via nuclear factor-kappaB inactivation. J. Agric. Food Chem., 2008, 56(21), 10265-10272.
268. McGill, M. R.; Du, K.; Weemhoff, J. L.; Jaeschke, H. Critical review of resveratrol in xenobiotic-induced hepatotoxicity. Food Chem. Toxicol., 2015, 86, 309-318.
269. Ni, Z. H.; Tang, J. H.; Chen, G.; Lai, Y. M.; Chen, Q. G.; Li, Z.; Yang, W.; Luo, X. M.; Wang, X. B. Resveratrol inhibits mucus overproduction and MUC5AC expression in a murine model of asthma. Mol. Med. Rep., 2016, 13(1), 287-294.
270. Steiner, N.; Balez, R.; Karunaweera, N.; Lind, J. M.; Munch, G.; Ooi, L. Neuroprotection of Neuro2a cells and the cytokine suppressive and anti-inflammatory mode of action of resveratrol in activated RAW264.7 macrophages and C8-B4 microglia. Neurochem. Int., 2016, 95, 46-54.
271. Ji, G.; Wang, Y.; Deng, Y.; Li, X.; Jiang, Z. Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy. Lipids Health Dis., 2015, 14, 134.
272. Liu, P. L.; Chong, I. W.; Lee, Y. C.; Tsai, J. R.; Wang, H. M.; Hsieh, C. C.; Kuo, H. F.; Liu, W. L.; Chen, Y. H.; Chen, H. L. Anti-inflammatory effects of resveratrol on hypoxia/reoxygenation-induced alveolar epithelial cell dysfunction. J. Agric. Food Chem., 2015, 63(43), 9480-9487.
273. Kaisar, M. A.; Prasad, S.; Cucullo, L. Protecting the BBB endothelium against cigarette smoke-induced oxidative stress using popular antioxidants: Are they really beneficial? Brain Res., 2015, 1627, 90-100.
274. Cheng, L.; Jin, Z.; Zhao, R.; Ren, K.; Deng, C.; Yu, S. Resveratrol attenuates inflammation and oxidative stress induced by myocardial ischemia-reperfusion injury: role of Nrf2/ARE pathway. Int. J. Clin. Exp. Med., 2015, 8(7), 10420-10428.
275. Riccioni, G.; Gammone, M. A.; Tettamanti, G.; Bergante, S.; Pluchinotta, F. R.; D'Orazio, N. Resveratrol and antiatherogenic effects. Int. J. Food Sci. Nutr., 2015, 66(6), 603-610.
276. Sadarani, B. N.; Majumdar, A. S. Resveratrol potentiates the effect of dexamethasone in rat model of acute lung inflammation. Int. Immunopharmacol., 2015, 28(1), 773-779.
277. Faghihzadeh, F.; Adibi, P.; Hekmatdoost, A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br. J. Nutr., 2015, 114(5), 796-803.
278. Moilanen, L. J.; Hamalainen, M.; Lehtimaki, L.; Nieminen, R. M.; Muraki, K.; Moilanen, E. Pinosylvin inhibits TRPA1-induced calcium influx in vitro and trpa1-mediated acute paw inflammation in vivo. Basic Clin. Pharmacol. Toxicol., 2015.
279. Lim, S. J.; Kim, M.; Randy, A.; Nho, C. W. Inhibitory effect of the branches of Hovenia dulcis Thunb. and its constituent pinosylvin on the activities of IgE-mediated mast cells and passive cutaneous anaphylaxis in mice. Food Funct., 2015, 6(4), 1361-1370.
280. Bauerova, K.; Acquaviva, A.; Ponist, S.; Gardi, C.; Vecchio, D.; Drafi, F.; Arezzini, B.; Bezakova, L.; Kuncirova, V.; Mihalova, D.; Nosal, R. Markers of inflammation and oxidative stress studied in adjuvant-induced arthritis in the rat on systemic and local level affected by pinosylvin and methotrexate and their combination. Autoimmunity, 2015, 48(1), 46-56.
281. Yum, S.; Jeong, S.; Lee, S.; Nam, J.; Kim, W.; Yoo, J. W.; Kim, M. S.; Lee, B. L.; Jung, Y. Colon-targeted delivery of piceatannol enhances anti-colitic effects of the natural product: potential molecular mechanisms for therapeutic enhancement. Drug Des. Devel. Ther., 2015, 9, 4247-4258.
282. Shiratake, S.; Nakahara, T.; Iwahashi, H.; Onodera, T.; Mizushina, Y. Rose myrtle (Rhodomyrtus tomentosa) extract and its component, piceatannol, enhance the activity of DNA polymerase and suppress the inflammatory response elicited by UVB.induced DNA damage in skin cells. Mol. Med. Rep., 2015, 12(4), 5857-5864.
283. Kalariya, N. M.; Shoeb, M.; Reddy, A. B.; Sawhney, R.; Ramana, K. V. Piceatannol suppresses endotoxin-induced ocular inflammation in rats. Int. Immunopharmacol., 2013, 17(2), 439-446.
284. Ko, Y. J.; Kim, H. H.; Kim, E. J.; Katakura, Y.; Lee, W. S.; Kim, G. S.; Ryu, C. H. Piceatannol inhibits mast cellmediated allergic inflammation. Int. J. Mol. Med., 2013, 31(4), 951-958.
285. Kim, Y. H.; Kwon, H. S.; Kim, D. H.; Cho, H. J.; Lee, H. S.; Jun, J. G.; Park, J. H.; Kim, J. K. Piceatannol, a stilbene present in grapes, attenuates dextran sulfate sodium-induced colitis. Int. Immunopharmacol., 2008, 8(12), 1695-1702.
286. Pterostilbene attenuates inflammation in rat heart subjected to ischemia-reperfusion: role of TLR4/NF-κB signaling pathway [Retraction]. Int. J. Clin. Exp. Med., 2015, 8(8), 14565.
287. Poulose, S. M.; Thangthaeng, N.; Miller, M. G.; Shukitt-Hale, B. Effects of pterostilbene and resveratrol on brain and behavior. Neurochem. Int., 2015, 89, 227-233.
288. Wang, W.; Ding, X. Q.; Gu, T. T.; Song, L.; Li, J. M.; Xue, Q. C.; Kong, L. D. Pterostilbene and allopurinol reduce fructoseinduced podocyte oxidative stress and inflammation via microRNA-377. Free Radic. Biol. Med., 2015, 83, 214-226.
289. Perecko, T.; Drabikova, K.; Lojek, A.; Ciz, M.; Ponist, S.; Bauerova, K.; Nosal, R.; Harmatha, J.; Jancinova, V. The effects of pterostilbene on neutrophil activity in experimental model of arthritis. BioMed Res. Int., 2013, 2013, 106041.
290. McCormack, D.; McFadden, D. A review of pterostilbene antioxidant activity and disease modification. Oxid. Med. Cell. Longev., 2013, 2013, 575482.
291. Chang, J.; Rimando, A.; Pallas, M.; Camins, A.; Porquet, D.; Reeves, J.; Shukitt-Hale, B.; Smith, M. A.; Joseph, J. A.; Casadesus, G. Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease. Neurobiol. Aging, 2012, 33(9), 2062-2071.
292. Vasconcelos, J. F.; Teixeira, M. M.; Barbosa-Filho, J. M.; Agra, M. F.; Nunes, X. P.; Giulietti, A. M.; Ribeiro-Dos-Santos, R.; Soares, M. B. Effects of umbelliferone in a murine model of allergic airway inflammation. Eur. J. Pharmacol., 2009, 609(1-3), 126-131.
293. Sim, M. O.; Lee, H. I.; Ham, J. R.; Seo, K. I.; Kim, M. J.; Lee, M. K. Anti-inflammatory and antioxidant effects of umbelliferone in chronic alcohol-fed rats. Nutr. Res. Pract., 2015, 9(4), 364-369.
294. Jin, H.; Wang, L.; Xu, C.; Li, B.; Luo, Q.; Wu, J.; Lv, Y.; Wang, G.; Dong, J. Effects of Psoraleae fructus and its major component psoralen on Th2 response in allergic asthma. Am. J. Chin. Med., 2014, 42(3), 665-678.
295. Liu, F.; Sun, G. Q.; Gao, H. Y.; Li, R. S.; Soromou, L. W.; Chen, N.; Deng, Y. H.; Feng, H. H. Angelicin regulates LPSinduced inflammation via inhibiting MAPK/NF-κB pathways. J. Surg. Res., 2013, 185(1), 300-309.
296. Carrasco-Pozo, C.; Castillo, R. L.; Beltran, C.; Miranda, A.; Fuentes, J.; Gotteland, M. Molecular mechanisms of gastrointestinal protection by quercetin against indomethacininduced damage: role of NF-kappaB and Nrf2. J. Nutr. Biochem., 2015.
297. Kim, C. S.; Kwon, Y.; Choe, S. Y.; Hong, S. M.; Yoo, H.; Goto, T.; Kawada, T.; Choi, H. S.; Joe, Y.; Chung, H. T.; Yu, R. Quercetin reduces obesity-induced hepatosteatosis by enhancing mitochondrial oxidative metabolism via heme oxygenase-1. Nutr. Metab. (Lond), 2015, 12, 33.
298. Gardi, C.; Bauerova, K.; Stringa, B.; Kuncirova, V.; Slovak, L.; Ponist, S.; Drafi, F.; Bezakova, L.; Tedesco, I.; Acquaviva, A.; Bilotto, S.; Russo, G. L. Quercetin reduced inflammation and increased antioxidant defense in rat adjuvant arthritis. Arch. Biochem. Biophys., 2015, 583, 150-157.
299. Elbe, H.; Esrefoglu, M.; Vardi, N.; Taslidere, E.; Ozerol, E.; Tanbek, K. Melatonin, quercetin and resveratrol attenuates oxidative hepatocellular injury in streptozotocin-induced diabetic rats. Hum. Exp. Toxicol., 2015, 34(9), 859-868.
300. Seo, M. J.; Lee, Y. J.; Hwang, J. H.; Kim, K. J.; Lee, B. Y. The inhibitory effects of quercetin on obesity and obesityinduced inflammation by regulation of MAPK signaling. J. Nutr. Biochem., 2015, 26(11), 1308-1316.
301. Ma, J. Q.; Li, Z.; Xie, W. R.; Liu, C. M.; Liu, S. S. Quercetin protects mouse liver against CCl.-induced inflammation by the TLR2/4 and MAPK/NF-κB pathway. Int. Immunopharmacol., 2015, 28(1), 531-539.
302. Wang, L. L.; Zhang, Z. C.; Hassan, W.; Li, Y.; Liu, J.; Shang, J. Amelioration of free fatty acid-induced fatty liver by quercetin-3-O-beta-D-glucuronide through modulation of peroxisome proliferator-activated receptor-alpha/sterol regulatory element-binding protein-1c signaling. Hepatol. Res., 2015, 46(2), 225-238.
303. Huang, R.; Zhong, T.; Wu, H. Quercetin protects against lipopolysaccharide-induced acute lung injury in rats through suppression of inflammation and oxidative stress. Arch. Med. Sci., 2015, 11(2), 427-432.
304. Dajas, F.; Abin-Carriquiry, J. A.; Arredondo, F.; Blasina, F.; Echeverry, C.; Martinez, M.; Rivera, F.; Vaamonde, L. Quercetin in brain diseases: Potential and limits. Neurochem. Int., 2015, 89, 140-148.
305. Dodda, D.; Chhajed, R.; Mishra, J. Protective effect of quercetin against acetic acid induced inflammatory bowel disease (IBD) like symptoms in rats: possible morphological and biochemical alterations. Pharmacol. Rep., 2014, 66(1), 169-173.
306. Luo, C.; Yang, H.; Tang, C.; Yao, G.; Kong, L.; He, H.; Zhou, Y. Kaempferol alleviates insulin resistance via hepatic IKK/NF-κB signal in type 2 diabetic rats. Int. Immunopharmacol., 2015, 28(1), 744-750.
307. Yang, Q. S.; He, L. P.; Zhou, X. L.; Zhao, Y.; Shen, J.; Xu, P.; Ni, S. Z. Kaempferol pretreatment modulates systemic inflammation and oxidative stress following hemorrhagic shock in mice. Chin. Med., 2015, 10, 6.
308. Chung, M. J.; Pandey, R. P.; Choi, J. W.; Sohng, J. K.; Choi, D. J.; Park, Y. I. Inhibitory effects of kaempferol-3-Orhamnoside on ovalbumin-induced lung inflammation in a mouse model of allergic asthma. Int. Immunopharmacol., 2015, 25(2), 302-310.
309. Rajendran, P.; Rengarajan, T.; Nandakumar, N.; Palaniswami, R.; Nishigaki, Y.; Nishigaki, I. Kaempferol, a potential cytostatic and cure for inflammatory disorders. Eur. J. Med. Chem., 2014, 86, 103-112.
310. Latief, N.; Anand, S.; Lingaraju, M. C.; Balaganur, V.; Pathak, N. N.; Kalra, J.; Kumar, D.; Bhadoria, B. K.; Tandan, S. K. Effect of trimeric myricetin rhamnoside (TMR) in carrageenan-induced inflammation and caecal ligation and puncture-induced lung oxidative stress in mice. Phytother. Res., 2015, 29(11), 1798-1805.
311. Choi, H. N.; Kang, M. J.; Lee, S. J.; Kim, J. I. Ameliorative effect of myricetin on insulin resistance in mice fed a highfat, high-sucrose diet. Nutr. Res. Pract., 2014, 8(5), 544-549.
312. Liu, Y. N.; Zha, W. J.; Ma, Y.; Chen, F. F.; Zhu, W.; Ge, A.; Zeng, X. N.; Huang, M. Galangin attenuates airway remodelling by inhibiting TGF-β1-mediated ROS generation and MAPK/Akt phosphorylation in asthma. Sci. Rep., 2015, 5, 11758.
313. Jung, Y. C.; Kim, M. E.; Yoon, J. H.; Park, P. R.; Youn, H. Y.; Lee, H. W.; Lee, J. S. Anti-inflammatory effects of galangin on lipopolysaccharide-activated macrophages via ERK and NF-κB pathway regulation. Immunopharmacol. Immunotoxicol., 2014, 36(6), 426-432.
314. Shu, Y. S.; Tao, W.; Miao, Q. B.; Lu, S. C.; Zhu, Y. B. Galangin dampens mice lipopolysaccharide-induced acute lung injury. Inflammation, 2014, 37(5), 1661-1668.
315. Choi, J. K.; Kim, S. H. Inhibitory effect of galangin on atopic dermatitis-like skin lesions. Food Chem. Toxicol., 2014, 68, 135-141.
316. Zha, W. J.; Qian, Y.; Shen, Y.; Du, Q.; Chen, F. F.; Wu, Z. Z.; Li, X.; Huang, M. Galangin Abrogates Ovalbumin-Induced Airway Inflammation via Negative Regulation of NF-kappaB. Evid.-based Complement. Alternat. Med., 2013, 13, 767689.
317. Kim, H. H.; Bae, Y.; Kim, S. H. Galangin attenuates mast cell-mediated allergic inflammation. Food Chem. Toxicol., 2013, 57, 209-216.
318. Seo, S. H.; Jeong, G. S. Fisetin inhibits TNF-α-induced inflammatory action and hydrogen peroxide-induced oxidative damage in human keratinocyte HaCaT cells through PI3K/AKT/Nrf-2-mediated heme oxygenase-1 expression. Int. Immunopharmacol., 2015, 29(2), 246-253.
319. Feng, G.; Jiang, Z. Y.; Sun, B.; Fu, J.; Li, T. Z. Fisetin alleviates lipopolysaccharide-induced acute lung injury via TLR4-mediated NF-kappaB signaling pathway in rats. Inflammation, 2015.
320. Pal, H. C.; Athar, M.; Elmets, C. A.; Afaq, F. Fisetin inhibits UVB-induced cutaneous inflammation and activation of PI3K/AKT/NFκB signaling pathways in SKH-1 hairless mice. Photochem. Photobiol., 2015, 91(1), 225-234.
321. Kwak, S.; Ku, S. K.; Bae, J. S. Fisetin inhibits high-glucoseinduced vascular inflammation in vitro and in vivo. Inflamm. Res., 2014, 63(9), 779-787.
322. Basios, N.; Lampropoulos, P.; Papalois, A.; Lambropoulou, M.; Pitiakoudis, M. K.; Kotini, A.; Simopoulos, C.; Tsaroucha, A. K. Apigenin attenuates inflammation in experimentally induced acute pancreatitis-associated lung injury. J. Invest. Surg., 2015, [Epub ahead of Print].
323. Li, R.; Wang, X.; Qin, T.; Qu, R.; Ma, S. Apigenin ameliorates chronic mild stress-induced depressive behavior by inhibiting interleukin-1β production and NLRP3 inflammasome activation in the rat brain. Behav. Brain Res., 2016, 296, 318-325.
324. Patil, R. H.; Babu, R. L.; Naveen Kumar, M.; Kiran Kumar, K. M.; Hegde, S. M.; Nagesh, R.; Ramesh, G. T.; Sharma, S. C. Anti-Inflammatory Effect of Apigenin on LPS-Induced Pro-Inflammatory Mediators and AP-1 Factors in Human Lung Epithelial Cells. Inflammation, 2016, 39(1), 138-147.
325. Zhang, T.; Su, J.; Guo, B.; Wang, K.; Li, X.; Liang, G. Apigenin protects blood-brain barrier and ameliorates early brain injury by inhibiting TLR4-mediated inflammatory pathway in subarachnoid hemorrhage rats. Int. Immunopharmacol., 2015, 28(1), 79-87.
326. Zhang, K.; Ge, Z.; Xue, Z.; Huang, W.; Mei, M.; Zhang, Q.; Li, Y.; Li, W.; Zhang, Z.; Zhang, Z.; Zhang, L.; Wang, H.; Cai, J.; Yao, Z.; Zhang, R.; Da, Y. Chrysin suppresses human CD14 (+) monocyte-derived dendritic cells and ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol., 2015, 288, 13-20.
327. Shen, Y.; Tian, P.; Li, D.; Wu, Y.; Wan, C.; Yang, T.; Chen, L.; Wang, T.; Wen, F. Chrysin suppresses cigarette smoke-induced airway inflammation in mice. Int. J. Clin. Exp. Med., 2015, 8(2), 2001-2008.
328. Ali, B. H.; Adham, S. A.; Al Za'abi, M.; Waly, M. I.; Yasin, J.; Nemmar, A.; Schupp, N. Ameliorative effect of chrysin on adenine-induced chronic kidney disease in rats. PLoS One, 2015, 10(4), e0125285.
329. Rehman, M. U.; Ali, N.; Rashid, S.; Jain, T.; Nafees, S.; Tahir, M.; Khan, A. Q.; Lateef, A.; Khan, R.; Hamiza, O. O.; Kazim, S.; Qamar, W.; Sultana, S. Alleviation of hepatic injury by chrysin in cisplatin administered rats: probable role of oxidative and inflammatory markers. Pharmacol. Rep., 2014, 66(6), 1050-1059.
330. Yao, Y.; Chen, L.; Xiao, J.; Wang, C.; Jiang, W.; Zhang, R.; Hao, J. Chrysin protects against focal cerebral ischemia/reperfusion injury in mice through attenuation of oxidative stress and inflammation. Int. J. Mol. Sci., 2014, 15(11), 20913-20926.
331. Sagawa, H.; Naiki-Ito, A.; Kato, H.; Naiki, T.; Yamashita, Y.; Suzuki, S.; Sato, S.; Shiomi, K.; Kato, A.; Kuno, T.; Matsuo, Y.; Kimura, M.; Takeyama, H.; Takahashi, S. Connexin 32 and luteolin play protective roles in non-alcoholic steatohepatitis development and its related hepatocarcinogenesis in rats. Carcinogenesis, 2015, 36(12), 1539-1549.
332. Chen, Y.; Sun, X. B.; Lu, H. E.; Wang, F.; Fan, X. H. Effect of luteoin in delaying cataract in STZ-induced diabetic rats. Arch. Pharm. Res., 2015, [Epub ahead of Print].
333. Theoharides, T. C.; Stewart, J. M.; Hatziagelaki, E.; Kolaitis, G. Brain "fog", inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin. Front. Neurosci., 2015, 9, 225.
334. Xu, Y.; Zhang, J.; Liu, J.; Li, S.; Li, C.; Wang, W.; Ma, R.; Liu, Y. Luteolin attenuate the D-galactose-induced renal damage by attenuation of oxidative stress and inflammation. Nat. Prod. Res., 2015, 29(11), 1078-1082.
335. Jia, Z.; Nallasamy, P.; Liu, D.; Shah, H.; Li, J. Z.; Chitrakar, R.; Si, H.; McCormick, J.; Zhu, H.; Zhen, W.; Li, Y. Luteolin protects against vascular inflammation in mice and TNFalphainduced monocyte adhesion to endothelial cells via suppressing IKBα/NF-κB signaling pathway. J. Nutr. Biochem., 2015, 26(3), 293-302.
336. Shi, F.; Zhou, D.; Ji, Z.; Xu, Z.; Yang, H. Anti-arthritic activity of luteolin in Freund's complete adjuvant-induced arthritis in rats by suppressing P2X4 pathway. Chem. Biol. Interact., 2015, 226, 82-87.
337. Vazquez Prieto, M. A.; Bettaieb, A.; Rodriguez Lanzi, C.; Soto, V. C.; Perdicaro, D. J.; Galmarini, C. R.; Haj, F. G.; Miatello, R. M.; Oteiza, P. I. Catechin and quercetin attenuate adipose inflammation in fructose-fed rats and 3T3-L1 adipocytes Mol. Nutr. Food Res,. 2015, 59(4), 622-633.
338. Wong, K. L.; Wu, Y. R.; Cheng, K. S.; Chan, P.; Cheung, C. W.; Lu, D. Y.; Su, T. H.; Liu, Z. M.; Leung, Y. M. Palmitic acid-induced lipotoxicity and protection by (+)-catechin in rat cortical astrocytes. Pharmacol. Rep., 2014, 66(6), 1106-1113.
339. Zhu, D.; Wang, L.; Zhou, Q.; Yan, S.; Li, Z.; Sheng, J.; Zhang, W. (+)-Catechin ameliorates diabetic nephropathy by trapping methylglyoxal in type 2 diabetic mice. Mol. Nutr. Food Res., 2014, 58(12), 2249-2260.
340. Prince, P. D.; Lanzi, C. R.; Toblli, J. E.; Elesgaray, R.; Oteiza, P. I.; Fraga, C. G.; Galleano, M. Dietary (-) - epicatechin mitigates oxidative stress, NO metabolism alterations, and inflammation in renal cortex from fructosefed rats. Free Radic. Biol. Med., 2016, 90, 35-46.
341. Morrison, M.; Van Der Heijden, R.; Heeringa, P.; Kaijzel, E.; Verschuren, L.; Blomhoff, R.; Kooistra, T.; Kleemann, R. Epicatechin attenuates atherosclerosis and exerts antiinflammatory effects on diet-induced human-CRP and NFκB in vivo. Atherosclerosis, 2014, 233(1), 149-156.
342. Lv, J.; Feng, M.; Zhang, L.; Wan, X.; Zeng, Y. C.; Liang, P. F.; Xu, A. P. Protective effect of epigallocatechin gallate, a major constituent of green tea, against renal ischemiareperfusion injury in rats. Int. Urol. Nephrol., 2015, 47(8), 1429-1435.
343. Ding, Y.; Sun, X.; Chen, Y.; Deng, Y.; Qian, K. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Eur. J. Pharmacol., 2015, 761, 405-412.
344. Liu, W.; Dong, M.; Bo, L.; Li, C.; Liu, Q.; Li, Y.; Ma, L.; Xie, Y.; Fu, E.; Mu, D.; Pan, L.; Jin, F.; Li, Z. Epigallocatechin-3-gallate ameliorates seawater aspiration-induced acute lung injury via regulating inflammatory cytokines and inhibiting JAK/STAT1 pathway in rats. Mediators Inflamm., 2014, 2014, 612593.
345. Yang, E. J.; Lee, J.; Lee, S. Y.; Kim, E. K.; Moon, Y. M.; Jung, Y. O.; Park, S. H.; Cho, M. L. EGCG attenuates autoimmune arthritis by inhibition of STAT3 and HIF-1α with Th17/Treg control. PLoS One, 2014, 9(2), e86062.
346. Zhang, W. Y.; Lee, J. J.; Kim, Y.; Kim, I. S.; Han, J. H.; Lee, S. G.; Ahn, M. J.; Jung, S. H.; Myung, C. S. Effect of eriodictyol on glucose uptake and insulin resistance in vitro. J. Agric. Food Chem., 2012, 60(31), 7652-7658.
347. Ma, H.; Feng, X.; Ding, S. Hesperetin attenuates ventilatorinduced acute lung injury through inhibition of NF-κBmediated inflammation. Eur. J. Pharmacol., 2015, 769, 333-341.
348. Shimouchi, A.; Yokota, H.; Ono, S.; Matsumoto, C.; Tamai, T.; Takumi, H.; Narayanan, S. P.; Kimura, S.; Kobayashi, H.; Caldwell, R. B.; Nagaoka, T.; Yoshida, A. Neuroprotective effect of water-dispersible hesperetin in retinal ischemia reperfusion injury. Jap. J. Ophthalmol., 2016, 60(1), 51-61.
349. Kumar, B.; Gupta, S. K.; Srinivasan, B. P.; Nag, T. C.; Srivastava, S.; Saxena, R.; Jha, K. A. Hesperetin rescues retinal oxidative stress, neuroinflammation and apoptosis in diabetic rats. Microvasc. Res., 2013, 87, 65-74.
350. Chtourou, Y.; Kamoun, Z.; Zarrouk, W.; Kebieche, M.; Kallel, C.; Gdoura, R.; Fetoui, H. Naringenin ameliorates renal and platelet purinergic signalling alterations in highcholesterol fed rats through the suppression of ROS and NF-kappaB signaling pathways. Food Funct., 2016, 7(1), 183-193.
351. Al-Rejaie, S. S.; Aleisa, A. M.; Abuohashish, H. M.; Parmar, M. Y.; Ola, M. S.; Al-Hosaini, A. A.; Ahmed, M. M. Naringenin neutralises oxidative stress and nerve growth factor discrepancy in experimental diabetic neuropathy. Neurol. Res., 2015, 37(10), 924-933.
352. Martinez, R. M.; Pinho-Ribeiro, F. A.; Steffen, V. S.; Caviglione, C. V.; Vignoli, J. A.; Barbosa, D. S.; Baracat, M. M.; Georgetti, S. R.; Verri, W. A., Jr; Casagrande, R.; Naringenin Inhibits, U. V. Naringenin Inhibits UVB Irradiation-Induced Inflammation and Oxidative Stress in the Skin of Hairless Mice. J. Nat. Prod., 2015, 78(7), 1647-1655.
353. Orhan, I. E.; Nabavi, S. F.; Daglia, M.; Tenore, G. C.; Mansouri, K.; Nabavi, S. M. Naringenin and atherosclerosis: a review of literature. Curr. Pharm. Biotechnol., 2015, 16(3), 245-251.
354. Yoshida, H.; Watanabe, H.; Ishida, A.; Watanabe, W.; Narumi, K.; Atsumi, T.; Sugita, C.; Kurokawa, M. Naringenin suppresses macrophage infiltration into adipose tissue in an early phase of high-fat diet-induced obesity. Biochem. Biophys. Res. Commun., 2014, 454(1), 95-101.
355. Zhu, L.; Wang, J.; Wei, T.; Gao, J.; He, H.; Chang, X.; Yan, T. Effects of Naringenin on inflammation in complete freund's adjuvant-induced arthritis by regulating Bax/Bcl-2 balance. Inflammation, 2015, 38(1), 245-251.
356. Bhaswant, M.; Fanning, K.; Netzel, M.; Mathai, M. L.; Panchal, S. K.; Brown, L. Cyanidin 3-glucoside improves diet-induced metabolic syndrome in rats. Pharmacol. Res., 2015, 102, 208-217.
357. Yan, X.; Wu, L.; Li, B.; Meng, X.; Dai, H.; Zheng, Y.; Fu, J. Cyanidin-3-O-glucoside attenuates acute lung injury in sepsis rats. J. Surg. Res., 2015, 199(2), 592-600.
358. Pratheeshkumar, P.; Son, Y. O.; Wang, X.; Divya, S. P.; Joseph, B.; Hitron, J. A.; Wang, L.; Kim, D.; Yin, Y.; Roy, R. V.; Lu, J.; Zhang, Z.; Wang, Y.; Shi, X. Cyanidin-3-glucoside inhibits UVB-induced oxidative damage and inflammation by regulating MAP kinase and NF-κB signaling pathways in SKH-1 hairless mice skin. Toxicol. Appl. Pharmacol., 2014, 280(1), 127-137.
359. Decendit, A.; Mamani-Matsuda, M.; Aumont, V.; Waffo-Teguo, P.; Moynet, D.; Boniface, K.; Richard, E.; Krisa, S.; Rambert, J.; Merillon, J. M.; Mossalayi, M. D. Malvidin-3-O-β glucoside, major grape anthocyanin, inhibits human macrophage-derived inflammatory mediators and decreases clinical scores in arthritic rats. Biochem. Pharmacol., 2013, 86(10), 1461-1467.
360. Pal, H. C.; Chamcheu, J. C.; Adhami, V. M.; Wood, G. S.; Elmets, C. A.; Mukhtar, H.; Afaq, F. Topical application of delphinidin reduces psoriasiform lesions in the flaky skin mouse model by inducing epidermal differentiation and inhibiting inflammation. Br. J. Dermatol., 2015, 172(2), 354-364.
361. Dayoub, O.; Andriantsitohaina, R.; Clere, N. Pleiotropic beneficial effects of epigallocatechin gallate, quercetin and delphinidin on cardiovascular diseases associated with endothelial dysfunction. Cardiovasc. Hematol. Agents Med. Chem., 2013, 11(4), 249-264.
362. Gupta, S. K.; Dongare, S.; Mathur, R.; Mohanty, I. R.; Srivastava, S.; Mathur, S.; Nag, T. C. Genistein ameliorates cardiac inflammation and oxidative stress in streptozotocininduced diabetic cardiomyopathy in rats. Mol. Cell. Biochem., 2015, 408(1-2), 63-72.
363. Nabavi, S. F.; Daglia, M.; Tundis, R.; Loizzo, M. R.; Sobarzo-Sanchez, E.; Orhan, I. E.; Nabavi, S. M. Genistein: A boon for mitigating ischemic stroke. Curr. Top. Med. Chem., 2015, 15(17), 1714-1721.
364. Yoo, N. Y.; Jeon, S.; Nam, Y.; Park, Y. J.; Won, S. B.; Kwon, Y. H. Dietary supplementation of genistein alleviates liver inflammation and fibrosis mediated by a methioninecholinedeficient diet in db/db mice. J. Agric. Food Chem., 2015, 63(17), 4305-4311.
365. Aras, A. B.; Guven, M.; Akman, T.; Alacam, H.; Kalkan, Y.; Silan, C.; Cosar, M. Genistein exerts neuroprotective effect on focal cerebral ischemia injury in rats. Inflammation, 2015, 38(3), 1311-1321.
366. Parida, S.; Singh, T. U.; Thangamalai, R.; Narasimha Reddy, ChE.; Panigrahi, M.; Kandasamy, K.; Singh, V.; Mishra, S. K. Daidzein pretreatment improves survival in mouse model of sepsis. J. Surg. Res., 2015, 197(2), 363-373.
367. Soumyakrishnan, S.; Divya, T.; Kalayarasan, S.; Sriram, N.; Sudhandiran, G. Daidzein exhibits anti-fibrotic effect by reducing the expressions of Proteinase activated receptor 2 and TGFβ1/smad mediated inflammation and apoptosis in Bleomycin-induced experimental pulmonary fibrosis. Biochimie, 2014, 103, 23-36.
368. Sakamoto, Y.; Naka, A.; Ohara, N.; Kondo, K.; Iida, K. Daidzein regulates proinflammatory adipokines thereby improving obesity-related inflammation through PPARγ. Mol. Nutr. Food Res., 2014, 58(4), 718-726.
369. Mohammad-Shahi, M.; Haidari, F.; Rashidi, B.; Saei, A. A.; Mahboob, S.; Rashidi, M. R. Comparison of the effects of genistein and daidzein with dexamethasone and soy protein on rheumatoid arthritis in rats. Bioimpacts, 2011, 1(3), 161-170.
370. Li, Z.; Dong, X.; Zhang, J.; Zeng, G.; Zhao, H.; Liu, Y.; Qiu, R.; Mo, L.; Ye, Y. Formononetin protects TBI rats against neurological lesions and the underlying mechanism. J. Neurol. Sci., 2014, 338(1-2), 112-117.